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Breast cancer, the most fiequent malignancy d in woen in the westem
world, is continuously i ndce i ind ial nations. Although breast cancer
develops in women as the meult ofa combiion ofeeal and donous factors such as
exosure toionizin rdiation, diet, Socioeconomic status, andendocrinologic, famili, orgenet-
icfactors, nospedficetiologicagent(s) orthe m anismsresponsibleofthe initition ofthedis-
ease has been identified asyeThus, e ment models that ehibit the same complex inter-
actions are needed fortestngvarious m anisms and for sig the enic pot ial of
givn emicals. Rodent mammarycarcinomas represent such amodel to agreat extentbecause,
in these species, mammary cancer is a muliep complex process that can be induced by either
hemicals, radiation, virn, or genetic ficors. Long-term studies in rodent models hae been
pculalyusefil for diing e initiation,promoton, andpro stepsof o
sis. The scpibit ofthe rodent m a dto op npsms has made this organ a
uniquetawgt fortsing the c genic potential ofsific geotoic hemcals ad viron-
mental agents. tumors idu by i - ordirect-actngc s such a 7,12-
dimeth (a)anthracene or A omethyl-N-nitrosourea are, ingeneal, horoedp denadle-
nocarcioms whose incidence, number oftumors per animal, tumorlatency, and tumor type
areinfluencedbytheage, repducie history, andendocrinologicmilieuofthehostatthe time
of ogen eposue. Rodentmodels areinformative intheabsenceofhuman data. Theyhave
provided valuable information on the dose and route ofadministration to be used andoptmal
host conditions for eliciting maximal tumorigenic rtsponse. Studies ofthe inuenc ofnorma
gland delopme on thepatogeneis ofc lly induced ma ary omas have clani-
fied t roleofdifferenation in cancerinitiaton. Comprve sadies with the dopment of
the human breast and the pathoe ofbrest cncer have contributed tovalidate rodent-to-
human eolations. However, it has not been definit established what type ofinforma-
tion is neceman risk assessment, whether currnt methodologies are
sufficient for ffilling those needs, or whether treatment-induced tu"noieic responses in
rodents are edictie ofpotential human risk. An lte ie to the adiiona biases
mechanism-based tocology andmolecular andcdulaarapproaches, combinedwithcompa
in vi*o sytem. These appohs talow the rapid sren ofc for tdngpriori-
ties for fiu-ther studies to determine the dose-rponse reatonhip for chemical effects at low
doses, to ae effects other d muna and/or origenis, or to establish qualiiv
and qrelationships ofbiomakers to toxic.e&cts. Until there is enough information
onthepIctive valueofmehanism-basedtoxicology for riska this approh should
be used in conjunction with and vlidated by the taditional in viv long-trm bioasays. Iey
words breast cancer,chemically induced mammary esis,endocrine system, hormones,
rodent mammarygland, rodent tumormodel. Environ HeahPerspm 104:938-967(1996)
The mammary gland, a specialized accesso-
ry gland of the skin that characterizes the
mammalian species, is a frequent source of
tumors or neoplasms. The terms tumor and
neoplasm are applied indistinctly to either
benign or malignant lesions because tumor
(from the Latin tumere, to swell) means any
pathological enlargement or new growth, as
does neoplasm (from the Greek neos new +
plasma formation) (1); however, neither
term defines the true nature of a given
growth. Benign tumors are those that do
not invade adjacent tissues, do not metasta-
size to distant sites, and can be cured by
local excision. Malignant tumors, or cancer,
are neoplasms characterized by their ability
to invade, metastasize, and ultimately cause
the death ofthe host. They are called carci-
nomas when they are derived from epithe-
lial cells, or sarcomas ifthey are mesenchy-
mal in origin (2). The emphasis given here
to the dassification oftumors as benign or
malignant is due to the implications ofthe
diagnosis ofmalignancy because it affects
theepidemiology ofthe disease, the dinical
and therapeutic approaches, and the inter-
pretation ofexperimental data.
The most significant malignant neo-
plasm in the human breast is the adenocar-
cinoma. The understanding of this disease
requires amultiprongapproachthatencom-
passes epidemiologic and clinical data, as
well as adequate experimental systems for
evaluating risk assessment or for testing
chemopreventive andtherapeuticagents.
Breast cancer is the most frequent spon-
taneous malignancy diagnosed in women in
the western world. In the United States
alone, 182,000 new cases were diagnosed in
1994; its incidence has been increasing for
several decades (3-5). Data from continu-
ously operating cancer registries, such as the
one in the state of Connecticut and the
Surveillance, Epidemiology, and End Results
(SEER) program established by the National
CancerInstitute in 1973 (which collects data
from nine population-based cancer registries
covering about 10% ofthe US population),
reveal that the age-adjusted incidence of
breastcancerroseatarateof1.2%/yearfrom
1940 to 1980; it rose even more steeply in
the next 7 years, reaching a peak of 112.4
cases/100,000 women in 1987, although it
decreased to 104.6 cases/100,000 women by
1989 (3-5). The increased incidence ofcan-
cer has been pardyattributed to an improve-
ment in early detection, as indicated by the
progressively increased percentage ofpatients
with earlystage (0 to I) disease (from 45.2%
in 1985-1986 to 53.1% in 1991) and
decreased percentage ofpatients in stage II
and III disease (6). Early diagnosis has
improved the rates ofcure and prolonged
survival; however, stage-specific survival rates
have increased only slightly since the mid-
1970s, and breast cancer remains only sec-
ond to lung cancer as a cause ofdeath, caus-
ing46,000 deaths in 1994 (3-5).
From all experimental systems available
for the study of mammary cancer, rodent
models have been particularlyuseful, mainly
because spontaneous mammary tumors are
frequently observed in long-term studies
(7). They are the most common hormone-
dependent spontaneous neoplasms devel-
oped in several strains of female rats; their
development, which increases with aging, is
attributed to hormonal imbalances such as
the constant estrous that occurs in old
Sprague-Dawley rats (7-9;JT Stevens, per-
sonal communication). In mice, sponta-
neous mammary tumors are either linked to
the infection offemales with an exogenous
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mouse mammary tumor virus (MMTV) or
a less virulent endogenous provirus (9-11).
Nevertheless, mammary tumors are also
hormone dependent, as initially demon-
strated by Lathrop and Loeb, who reported
that ovariectomy at an early age either
inhibited or delayed the appearance of
mammary tumors in outbred mice (9).
The susceptibility ofthe rodent mamma-
ry gland to develop neoplasms has made this
organ a unique target for testing the carcino-
genic potential ofspecific chemicals. Several
carcinogens that induce mammary tumors in
both mice and rats have been extensively
studied in both species (9,12-36). Tumors
induced by administration of chemical car-
cinogens constitute useful tools for dissecting
the multistep process of carcinogenesis,
which involves initiation, promotion, and
progression, and serve as a baseline for test-
ingthe carcinogenic potential ofchemicals in
risk assessment (7,37). Chemically induced
mammary tumors are, in general, hormone-
dependent adenocarcinomas. Their inci-
dence, number of tumors per animal, and
tumor type are influenced by the age ofthe
host at the time of carcinogen exposure,
reproductive history, endocrinologic milieu,
and diet, among other factors. These factors,
in turn, influence the development and
degree of mammary gland differentiation
(38-41), which are subject to a multiplicity
of endocrine stimulatory and inhibitory
influences from embryogenesis onward
(39,40,42-44). If these influences are not
exerted in proper temporal, sequential, and
quantitative relationships, normal develop-
ment, differentiation, and function are
adversely affected (41). The development of
the mammary gland, in turn, cannot be sep-
aratedfrom its aging, aprocess thatmarkedly
influences the incidence of spontaneous
tumors in all strains ofrats (8,45,46), aswell
as in mice infectedwith MMTV (10).
The ideal animal tumor model should
mimic the human disease (23,47) by pro-
viding a model for ascertaining the influence
ofhost factors on the initiation oftumorige-
nesis, mimicking the tumorigenic response
elicited under specific age and reproductive
conditions, and determining the response of
the tumors induced to chemotherapy. The
use of experimental models of mammary
carcinogenesis in risk assessment requires
that the influence ofovarian, pituitary, and
placental hormones, as well as overall repro-
ductive events, and age at menarche and
menopause are taken into consideration
because they are important modifiers ofthe
susceptibility of the organ to neoplastic
development (9,41,48). Several species such
as rodents (9,41), dogs (49), cats (50), and
monkeys (51) have been evaluated for these
purposes; however, none of them fulfill all
the criteria specified above. Rodents, howev-
er, are the most widely used models
(24-36,41,47, 52). Therefore, this work
will discuss various aspects of the rodent
model such as 1) the normal anatomy and
development ofthe mammary gland during
reproductive events and aging; 2) the influ-
ence of reproductive, aging, and nongeno-
toxic factors on tumor development; 3)
experimental genotoxic-induced rodent
mammary tumor models; 4) modifiers of
susceptibility ofthe gland to neoplasia; and
5) impact of hormones and growth factors
on mammary carcinogenesis. In addition,
current knowledge on human breast cancer
will be briefly reviewed to establish a unify-
ing concept between human and rodent car-
cinogenesis.
Mammary Gland
Development
Anatomy ofthe Mammary Gland
Gross anatomy. The mammary gland,
whose function is the secretion of milk for
the nourishment ofthe offspring, adapts to
this function primarily by developing a
number of glands adequate for sustaining
the number ofnewborns that are character-
istic for a given species (41,47,53). In both
rats and mice, the mammary glands are
aligned ventrolaterally along the mammary
or milk lines from the cervical to the
inguinal regions. The only externally visible
portion of the mammary gland in the
female is the nipple, a cutaneous structure
located ventrolaterally, and from which the
rest of the mammary gland extends dorso-
laterally as flat subcutaneous sheets of
fibroadipose tissue (40,53). Male mice have
no nipples, and they usually have four pairs
of rudimentary glands consisting of major
branching ducts with no alveoli, primary
ducts, or openings to the exterior (53).
Female mice, on the other hand, have five
pairs ofmammary glands, one cervical, two
thoracic, and two abdominal-inguinal
pairs. The female rat has six pairs, the fifth
and sixth pairs being located in the inguinal
region. Except for the difference in total
number ofmammary glands in the females,
the anatomic location and distribution of
these paired organs is similar between these
two species; therefore, the descriptions
below apply indistinctly to both, unless oth-
erwise specified. No further description will
be done of the mammary gland in males
because it is an atrophic organ that rarely
gives origin to spontaneous tumors or is the
subject ofcarcinogenicity studies.
The size and distribution of the mam-
mary glands vary markedly as a function of
sex, age, hormonal stimulation, and repro-
ductive condition (23,39,40,54). Classical
descriptions of mammary gland distribu-
tion apply to the glands of fully mature
parous females in which the first pair, or
cervical mammary glands, extend cranially
to the parotid and mandibular salivary
glands and laterally along the medial aspect
of the forelimb, reaching the interscapular
fat pad. The second and third pairs are
located in the thoracic region, extending
laterally and dorsally from the nipples,
which are medially located. The two pairs
ofabdominal-inguinal glands in the female
mouse and the three pairs of abdomino-
inguinal glands in the female rat are in
Figure 1. Development of the fourth (abdominal) mammary gland of the female Sprague-Dawley rat.
Comparison of gland area and number and complexity of branching at 15 (x3.9), 30 (x3.4), and 55 (x5.6)
days ofage. n, nipple. Whole mount preparations, toluidine blue (x3).
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Figure 2 Schematic representation ofthefourth (abdominal) mammary gland of a 55 day-old virgin female
rat The gland was divided intothree zones: A, proximal tothe nipple (n), contains more numerous lobules
type 1 (lob). Zone B, medial, encompasses the lymph node (LN). Zone C, distal to the nipple, contains the
majority ofactively growing terminal end buds (TEB); alveolar buds (AB) and terminal ducts (TD) are also
present From Russo and Russo (20).
Figure 3. Ultrastructure of a rat mammary gland
ductule. The epithelium is composed of intermedi-
ate (ic) and dark cells (dc) resting on a discontinu-
ous layerofmyoepithelial cells (m). Uranyl acetate-
lead citrate (x1400). From Russo etal. (40).
close continuity, extending medially in the
pubic region, caudally to the perianal
region, and laterally onto the medial aspect
ofthe hindlimbs (40,47,53-55).
Microscopic anatomy. The basic archi-
tecture of the mammary gland has been
extensively described as acomplex structure
composed of parenchyma and stroma
(40,42,44). The understanding of the
structure ofthe gland requires the study of
the complete organ in whole mount prepa-
rations (Fig. 1) combined with histological
sections representative ofspecific areas of
the same because different topographic
areas contain structures that differ in their
morphology, cell kinetic characteristics,
hormone responsiveness, and carcinogenic
potential (23).
The parenchyma consists ofone or two
major lactiferous ducts that grow from the
nipple into the surrounding fat pad. The
growth ofthe mammarygland occurs as the
result ofa combined process oflengthening
of major ducts in a straight fashion in the
areas doser to the nipple, which in the rat
has been called zone A (Fig. 2) (39,40,
54,55). A progressive dichotomous and
sympodial branching ofsmaller ducts and
lateral buds occurs more frequently in the
middle third of the gland (zone B). The
portion ofthe gland opposite to the nipple
(zone C) contains the mostactivelygrowing
terminal ductal structures, the terminal end
buds (TEBs) (Fig. 2) (15,22,23,39,40,
42,53). The mammary ducts are tubular
structures withwalls composed oftwo main
cell types, an internal layer ofepithelial cells
lining the lumen and an external and dis-
continuous layer ofmyoepithelial cells rest-
ing on the basement membrane (Fig. 3,4)
(40). Both the thickness of the epithelial
layer and its degree ofdifferentiation varyas
a function ofthe specific structure in which
they are located. Major ducts tend to be
lined by a single or pseudostratified layer of
low columnar or cuboidal epithelial cells.
The luminal border is fringed with short,
blunt microvilli. Adjacent cells interdigitate
and are joined bywell-developed junctional
complexes (42,56-58). TEBs, on the other
hand, are lined by a multilayered epitheli-
um composed of large cuboidal cells
exhibiting a high rate of cell proliferation
(Fig. 5) (40). In the mouse, the end bud
consists of four to six layers of cuboidal
epithefium. On the basal surface ofthe end
bud beneath the basal lamina are the cap
cells (5$ ). These cells lackdifferentiated fea-
tures: they lack cytoplasmic polarity, they
do not form cell junctions, and they do not
contain highly organized cytoskeletal ele-
ments. These cells are interpreted to repre-
sent a pluripotent stem cell population,
capable ofdifferentiating into both mam-
mary ductal and mammary myoepithelial
cell types (42). Ultrastructurally, the cells
composing theTEBs havebeen described as
intermediate cells (6,57) due to the moder-
ate electron density of the nudeus and the
cytoplasm, in contrast with the other two
cell types described in both the rat and the
mouse mammary glands, the dark and the
light cells (42,57-60). Intermediate cells
(Fig. 3-6) have a large round or oval nucle-
us and an abundant cytoplasm rich in
organelles, but show almost no secretory
activity. In contrast, dark cells (Fig. 3-6),
which are more numerous in ducts and
Figure 4. Lobule type 1 of the virgin rat mammary
gland. Each ductule or alveolus is lined by a sin-
gle layer of low cuboidal epithelium composed of
myoepithelial (m), intermediate (ic), and dark cells
(dc). Plastic embedded 1 pm section toluidine
blue (x270}.
secretoryalveoli, have smaller and convolut-
ed nudei and contain abundant cytoplasm
rich in ribosomes, Golgi complexes, lipid
droplets, and secretory vacuoles (40). The
external layer or myoepithelium is located
between the epithelial layer and the basal
lamina (Fig. 3,6). Myoepithelial cells
appear moderatelyelectron dense due to the
presence of thick bundles of tonofilaments
and myofibril-like bundles of actin and
myosin in the cytoplasm, a characteristic
that these cells share with smooth muscle
fibers. Their plasma membrane contains
numerous pinocytotic vesicles and is
attached to the basal lamina byhemidesmo-
somes (Fig. 3,6) (40). The basement mem-
brane on which the epi-myoepithelial com-
plex rests is composed of a bilayered basal
lamina: the lamina lucida, in dose contact
with the myoepithelium, and the lamina
densa, which forms a continuous sheath
between the lamina lucida and the stroma
(42,48,61-63).
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Figure 5. Composite showing the terminal end bud (TEB) of the virgin rat mammary gland in whole mount
(x50), longitudinal section of a plastic embedded TEB stained with toluidine blue (center, x1395); electron
micrograph ofintermediate (x3575), dark(x7125), and myoepithelial cells(x7500). Uranyl acetate-lead citrate.
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Figure 6. Electron micrograph ofthe terminal end bud ofthe virgin rat mammary gland. Myoepithelial cells
(M) rest on the electron dense basal lamina. Dark cells (DC) and intermediate cells (IC) form the multilay-
ered epithelium and emit microvilli toward the lumen. Uranyl acetate-lead citrate (x2275). From: Russo et
al. (40).
Prenatal and Postnatal Development
The developmental and functional states of
the mammary gland are subject to a multi-
plicity ofgenetically determined endocrine
stimulatory and inhibitory influences from
earlyembryogenesis through the senescence
ofthe individual. Studies ofthe sex differ-
ences in mammary gland histogenesis indi-
cate that the rodent mammary rudiment is
sensitive to the influences of gonadal
steroids during the prenatal stage
(44,64,65). In mice, sexual differentiation
of the gonads occurs on the late 13th day
of gestation, after which the testes start to
produce androgens in the male embryo.
On the 14th day, the sexual phenotype of
the mammary gland is determined (44). At
this time, the male mammary bud becomes
constricted at its epidermal junction and
ultimately becomes completely detached.
X-ray destruction of the fetal testes on the
13th day ofgestation causes the mammary
bud of the male to remain attached to the
epidermis and the duct primordia to ramify
similarly to the primordia of the female.
Testosterone injections into pregnant ani-
mals cause the mammary buds of female
embryos to undergo male-type develop-
ment (44). The milk-fed newborn is
exposed to a rich source ofgrowth factors;
these factors might play important roles in
the growth and development of the mam-
mary gland (66). One of the principal
growth factors present in milk is epidermal
growth factor (EGF), which is an impor-
tant regulator of mouse mammary epithe-
lial cell proliferation and differentiation
both in vivoand in vitro (67).
In the Sprague-Dawley rat, the mamma-
ry gland evolves from a primary main lactif-
erous duct; it branches into multiple sec-
ondary ducts, whose length and the number
ofbranches it originates increase with aging
ofthe animal (Fig. 1). Bythe secondweekof
postnatallife, the ductshave furthersprouted
to a sixth generation ofbranches, which end
in dub-shaped TEBs composed of three to
six layers of medium-sized epithelial cells
(Fig. 5,6). The number ofTEBs is maximal
when the rats are 21 days old; after this age,
TEBs begin to cleave into three to five small-
er buds or alveolar buds (ABs). The progres-
sive differentiation of TEBs into ABs is
accentuated by each estrous cycle, which
starts when the animals are 30-42 days old
(39). In the nonpregnant female, the devel-
opment ofthe mammary gland is rigorously
controlled by the ovary. Ovariectomy causes
regression of end buds and cessation of
growth (42). The ovary, in turn, depends on
pituitary gonadotropins for its development
and function. Pituitary luteinizing hormone
(LH) and follicle stimulating hormone
(FSH) interact with growth hormone (GH)
and prolactin (PRL) to modulate ovarian
steroidogenesis, as well as the secretion of
nonsteroidal glycoproteins such as inhibin
and activin (68-71). In general, estrogens
are responsible for growth of mammary
ducts and progesterone is necessary for lobu-
loalveolar growth in the mouse (72); howev-
er, a direct mitogenic effect of estrogens on
the mammary gland has not been clearly
demonstrated (73). Apostulated mechanism
is that estrogens stimulate secretion of
growth factors such as EGF (74) or other
growth factors ofmammary or extramamma-
ry origin that might sensitize the mammary
gland to mitogenic factors (73,75).
Estrogens, on the other hand, have a mito-
genic effect on several human breast cancer
cell lines. When estrogens and progesterone
are injected together, lobuloalveolar develop-
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ment is promoted, with inhibition oflacto-
genesis, probably through an indirect effect
by antagonizing glucocorticoid action that
blocks casein gene expression (76,77). The
mammogenic effects ofovarian steroids are
largely dependent on the integrity of the
pituitary gland, because the effects ofestro-
gen and progesterone cannot be demonstrat-
ed in hypophysectomized animals (78).
Ductal elongation and branching that occurs
during puberty is positively regulated by
ovarian estrogens and pituitary GH, which
in turn might act through its local mediator,
insulin-like growth factor I (IGF-I) (66).
Furthermore, in the rat, estrogens stimulate
the secretion ofpituitary PRL; this hormone,
rather than progesterone, appears to regulate
the lobuloalveolar development ofthe mam-
mary gland and exerts a direct effect on the
growth of the mammary parenchyma and
epithelium (67,79).
MammaryGland Development dur-
ingPregnancy
Pregnancy represents a completely novel
endocrinologic experience to the female
organism. The fertilized egg becomes a new
endocrine organ soon after conception.
The developing blastocyst and the placenta
represent a rich source of hormones and
growth factors, which, in conjunction with
fetal secretions, enter the maternal blood-
stream, thus influencing multiple target
organs (39). In the first pregnancy of a
young female rat, there are six pairs of
mammary glands that differ in their degree
ofdevelopment, depending upon the topo-
graphic location ofeach specific gland and
of the distance between the location of a
given parenchymal structure and the nipple
(Fig. 2) (39,80). Gland development is
also influenced by other factors, such as the
number of ovulatory cycles that have
occurred after the initiation of the ovarian
function, diet and specific genetic charac-
teristics ofthe animal (39,81,82).
At mating, the mammary glands con-
tain a large proportion ofTEBs, which are
more numerous in the zone C ofthe glands
(Fig. 2,6,7A,8A). They are also more
numerous in thoracic than abdominal
mammary glands. There are also ABs, but
few lobules are present (39). Cervical stim-
ulation at mating increases PRL levels,
which in turn increase the number ofovar-
ian luteal LH receptors, thus enhancing
steroidogenesis. Early in pregnancy, the
combined influences of ovarian estrogen,
progesterone, and inhibin (68,71), with
the production of rat chorionic
gonadotropin (rCG) and rat placental lac-
togen (rPL) by the developing embryo,
contribute to stimulate the mammary
glands to undergo active cell proliferation.
I ,U 12 ductules
Figure 7. (A) Terminal end buds (TEBs) located in Zone C ofthe mammary gland of a 55 day-old virgin rat.
(B) Lobules type 3 and 4 located in zone C ofthe mammary gland atthe end of pregnancy. Whole mount
preparations, toluidine blue (x150).
RO~~~~~~~~~~~~~~~~~~~~A
Figure . (A) Histological section of the terminal end buds shown in Figure lA showing a multilayered
epithelium and a narrow centrally located lumen (x362). (B) Lobules type 3 and 4 shown in Figure 7B are
composed of secretory alveoli lined by a single layer of low cuboidal epithelial cells; the lumen of the
alveoli is distended and milkfilled Ox39) H&E.
Greater activity is observed in TEBs, which
rapidly cleave to form ABs, thus diminish-
ing their number. ABs, in turn, progres-
sively differentiate into lobules (39). In
early pregnancy, the estrogen receptor con-
tent ofthe mammarygland becomes signif-
icantly higher than that ofvirgin rats (83).
Pituitary relaxin, which plays an important
role in the development ofthe nipples dur-
ing the second half of pregnancy, also
influences the development of lobules and
the lactational capacity of the mammary
glands (84).
During the gestational process,
immunocytochemical reactions with antil-
aminin and type IV collagen antibodies
reveal that the basement membrane
remains intact around the newly formed
lobules. Myosin-positive myoepithelial cells
are attenuated and discontinuous in the
alveoli, while they are prominent in the
main ducts (62,63). The alveolar epitheli-
um exhibits positive immunoreactivity
with inhibin antibodies, which reaches its
peak by the 15th day of pregnancy.
Thereafter, the reaction becomes more
intense in the perilobular stroma (85,86).
At the end of pregnancy, the mammary
gland is almost completely composed of
densely packed lobules (Fig. 7B,8B). They
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Table 1. Density ofterminal end buds(TEB),terminal ducts (TD), alveolar buds (AB), and lobules inthe rat
mammary gland
Groups Age (days) TEB TD AB Lobules
Young virgin 55 5.4 ± 0.3 5.5 ± 0.3 15.8 ± 2.1 1.2 ±0.3
Old virgin 180 0.6 ± 0.2 6.0 ± 2.1 14.8 ± 2.0 0.8 ± 1.2
Multiparous 180 0.0 0.7 ± 0.8 14.2 ± 4.5 3.4 ± 1.6
Age in days atthe time of 7,12-dimethylbenz(a)anthracene administration. All values listed representthe
mean ± SD of the number of structures per square millimeter of gland and reflect the structural state of
the gland atthe moment of DMBA administration.
Table 2. DNA labeling index ofterminal end buds(TEB),terminal ducts (TD), and alveolar buds(AB)
TEB TD AB
Labeled Labeled Labeled Labeled Labeled Labeled
Groups cells TEB cells TD cells AB
Young virgin 34.4±7.6 100 12.3±5.8 70 7.9±3.3 50
Old virgin 14.8 ±4.7 100 4.9±3.4 28 10.9± 1.7 5
Multiparous 0.0 0 0.3±0.5 8 0.3± 0.05 0.9
Labeled cells, number of cells incorporating 3H-thymidine/100 cells; labeled TEB, percentage ofTEB con-
taining labeled cells; labeled TD, percentage ofTD containing labeled cells; labeled AB, percentage ofAB
containing labeled cells. All labeled cell values listed representthe mean of percentages ± SD.
show active secretory activity in most acini.
Lumina are distended by milk and the aci-
nar lining epithelium has become a flat-
tened single layer oflowcuboidal cells (Fig.
8B), which stain positively with the anti-
body against milk fat globule membrane
antigen (62).
Lactation and Post-lactational
Involution
Immediately following parturition, the
estrogen receptor content of the mammary
gland, expressed as cytosolic estrogen recep-
tor/g DNA increases significantly over a
period of2 to 4 days, which coincides with
a period of DNA increase (83). Lactation,
which lasts up to 3 weeks, delays the reiniti-
ation of the estrous cycle and ovulation in
postpartum rats (68). During lactation PRL
levels are elevated, and the PRL receptor
mRNAs increase significantly in the mam-
mary glands, starting on the last day of
pregnancy and continuing to increase dur-
ing lactation (87). In the secretory acini of
the lactating gland, myoepithelial cells are
attenuated, with large gaps between cells
(63). The basement membrane remains
continuous, and fibronectin appears as a
new component, with a distribution similar
to that oftype IV collagen and laminin. As
in the mammary gland of pregnancy,
epithelial cells stain positivelywith antibody
against milk fat globule membrane antigen
(62). After weaning, PRL levels return to
normal and ovarian follicles develop into
preovulatory size, secreting 17,-estradiol in
quantities sufficient for inducing a preovu-
latory gonadotropin surge, which will
resume the normal estrous cyde (68). The
mammary gland exhibits an early increase
in weight, which reaches a peak value at 24
hr after weaning. From then on, the weight
dedines, reaches the initial value at approxi-
mately the third day, and becomes very low
bythe 10th daypost-weaningwhen mostof
the parenchyma is replaced by fat (88). The
involution ofthe mammarygland is accom-
panied by profound morphological and
physiological changes. The secretory alveo-
lar structures collapse, with active removal
of cells and secretions by macrophages.
There is an increase in the lysosomal
enzymes acid phosphatase and aryl sulfatase
in both epithelial cells and macrophages
(88). The collapsed alveolar structures form
large irregular dusters that contain epithe-
lial cells still reacting positively with milk
fat globule membrane antigen. The myoep-
ithelial cells become arranged in distorted
circular structures, and the basement mem-
brane acquires abroader appearance (62).
The Mammary Gland in theAging
Parous andNuiliparous Rat
Even though mammary gland involution
after weaning is apparently completed after
10 days ofpup removal, the architecture of
the organ remains permanently modified.
The mammary gland ofan animal that has
completed its first full term pregnancy and
lactation retains alarger numberofABs and
lobules. The comparative studyofthe archi-
tecture and cell kinetic characteristics ofthe
mammary gland of a multiparous animal
that has completed two pregnancies with
lactation, with that of a virgin rat of the
same age reveals that the involuted gland of
the multiparous rat has a general appear-
ance similar to that of the virgin animal.
However, quantitative differences exist. By
40-42 days post weaning, the mammary
glands ofthe multiparous rats do not con-
:; ., ... .-
Figure 9. Autoradiogram of a terminal end bud
located in Zone C of the mammary gland of a 55
day-old virgin rat shows active incorporation of
3H-thymidine predominantly into ductal epithelial
cells. NTB2 nucleartrack emulsion, H&E( x333).
tain TEBs. Terminal ducts (TDs) are occa-
sionally seen; the number ofABs is about
the same, and the number oflobules is four
times higher than that observed in the age-
matchedvirgin rats (Table 1).
Determination of the DNA labeling
index (DNA-LI) by quantitation of the
number of nuclei that had incorporated
3H-thymidine (Fig. 9) revealed that 100%
ofthe TEBs present in the mammary gland
ofthe 180-day-old virgin rat contain prolif-
erating cells that incorporate the radiola-
beled precursor (16-18). However, the
number oflabeled cells per TEB is marked-
ly lower than in young virgin rats (aged
40-50 days). Aging reduces the percentage
of labeled cells from 34.4% (Fig. 8) to
14.8% (Table 2). The percentages of
labeled TDs and their DNA-LI is also
reduced in the old virgin rats. In the resting
glands of multiparous rats, TDs are rarely
observed and only 8.2% of them contain
labeled cells, with a very low DNA-LI. ABs
show notable differences in their DNA-LI
in the three groups under study (Table 2).
Young and old virgin rats have 50% and
5% oftheirABs labeled, respectively. In the
resting glands of multiparous rats, only
0.9% ofthe ABs are labeled and the num-
ber ofcells incorporating DNA precursor is
low. Lobular structures do not incorporate
DNA precursor into their epithelial cells,
andmyoepithelial cells areonlyoccasionally
labeled (16-18). The profound morpho-
logical and cell kinetic differences observed
between young and old virgin rats and
between old virgin and multiparous rats are
not the result of differences in circulating
hormonal levels because the levels of PRL
and estradiol are similar in the three groups
of animals studied (89). However, with
senescence, the circulating hormone levels
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are markedly altered compared to young
females (90); aged female Sprague-Dawley
rats have significantly lower FSH, estradiol,
and progesterone levels than young cyding
females. PRL levels on the other hand have
been shown to be elevated (91). These
changes in hormone levels manifest them-
selves with a lengthening ofcycle duration
as a precursor to acyclicity that occurs in
aged females (92,93). The binding ofestro-
gen to receptors in the pituitary, hypothala-
mus, uterus, and mammary gland is
decreased in aged noncyclingrats (94-97).
Influence of Reproductive,
Aging, and Nongenotoxic
Factors on Tumor
Development
Several hormones have a biologically signif-
icant influence on the normal development
of the mammary glands, as well as signifi-
cant effects on their normal functional
states. These multiple hormonal influences
act in concert for producing an integrated
response under the control ofthe hypothal-
amus-anterior pituitary system, which
plays primary roles in the development and
function of the mammary gland (98,99).
To evaluate the role ofhormones in mam-
mary gland neoplasia, it is helpful to review
hormonal influences on the normal devel-
opment and functional states ofthe gland.
Much of what is known about the
endocrine control and endocrine influences
on the development ofthe mammary gland
is derived from observations on the effect
ofhormone withdrawal through hypophy-
sectomy, adrenalectomy, or gonadectomy
or by manipulating tissue cultures
(64,65,100,101). Despite the complexity
ofthe endocrine systems, hormones can be
classified into two major categories: those
that are regulated by the central nervous
system (CNS), namely, the hypothala-
mus-anterior pituitary system and those
whose production is, for the most part,
independent ofthe CNS, i.e., hormones of
the peripheral system, which are regulated
more directlybytheir own effects (98).
Hypothalamus-Anterior Pituitary
System
The development, anatomy and physiology
of the pituitary gland and its relationship
with the hypothalamus have been extensive-
ly studied during the last two decades, espe-
cially in experimental animals, with the rat
being the animal most frequently used
(98,102). Although many pituitary hor-
mones have a common evolutionary origin,
extrapolations offindings obtained in differ-
ent animal species to human conditions are
difficult, especially due to differences in the
development and function of the pituitary
gland occurring with aging, a period in life
of extreme importance in the development
of mammary neoplasms. Senescence is fre-
quently associated with pituitary hyperplasia
and development of adenomas in various
strains ofrats, whereas in humans the anteri-
or lobe undergoes a slight or moderate invo-
lution, the pituitary weight decreases, and
the incidence ofadenomas is unchanged or
slightly reduced (102). There are also wide
differences in the morphology of the gland
during development among various strains
and among species. A description of the
anatomy and physiology of the hypothala-
mus-pituitary system is beyond the scope of
this review; therefore, only issues ofessential
importance for the comprehension of its
interaction with the development of the
mammary gland and its neoplasms will be
attempted here. Despite interspecies differ-
ences, it is possible to establish a common
pattern for this system (98,102). Ofimpor-
tance for the development ofthe mammary
gland is the pars distalis, or anterior lobe of
the hypophysis, which contains five cate-
gories of hormone-secreting cells: soma-
totropic cells, which secrete growth hor-
mone (GH); lactotropic cells, secreting PRL;
corticotropic cells, which secrete adrenocor-
ticotropic hormone (ACTH) and its related
peptides; thyrotropic cells, producing thy-
roid stimulating hormone (TSH); and
gonadotropic cells, which secrete both
luteinizing hormone (LH) and follicle stim-
ulating hormone (FSH); sometimes called
interstitial cell-stimulating hormone (ICSH)
because of its action on the interstitial cells
ofboth the ovary and the testis. The release
ofhormones from these cells occurs classi-
cally by extrusion ofsecretory granules. The
hypothalamic component of the axis is not
only important for control ofthe endocrine
system and reproduction but also for the
Table3. Hormonal role in normal mammary gland development
Hormone Physiological role
Adrenocorticotropic hormone (ACTH) Secretion and synthesis of cortisol and corticosterone by
adrenal cortex
Follicle-stimulating hormone (FSH) Stimulation of graafian follicles
Growth hormone (GH; somatotropin) Overall body growth and stimulation oflactogenic activity
Luteinizing hormone (LH) Stimulation of ovulation, estrogen secretion, formation ofthe
corpora lutea, and progesterone secretion
Oxytocin Stimulation of milk ejection by contracting of myoepithelial
cells of mammae
Prolactin (mammotropin) Stimulates mammae parenchyma, initiates and maintains
milk production
Thyroxine Maintenance of metabolic milieu, synergistic with insulin in
mammary ductgrowth
Insulin Stimulates mammary ductgrowth
From JTStevens (personal communication).
Table 4. Comparison ofthe response to hormonal stimuli between humans and rats
Humans Rats
The estrogen componentof oral contraceptives The estrogen componentoforal contraceptives
leadsto an increased incidence of does not leadto an increased incidence of
thromboembolic disease (103) thromboembolic disease (103)
Prolactin does not play a critical role in the Prolactin plays a critical role in estrual animals (105)
nonpregnant human (104)
Pituitarytumors are rarely seen in humans Administration ofestradiol subchronically induces
of either sex(106) pituitarytumors (107)
Reproductive aging isthe result of ovarian failure Reproductive aging isthe resultofneuroondocrine
ratherthan neuroendocrine failure (108) failure (107)
Ovarian failure is characterized bythe depletion of Neuroendocrine failure is characterized by a decline
the fixed supply ofprimary ovarian follicles (109) ofhypothalamic neurosecretory activityresufting in
an inabilityto stimulatethe preovulatorygonadotropin
(LH) surge essential forovulation(110)
At menopause, estrogen and progesterone Loss ofthe preovulatory surge leadsto an arrested
secretion decline and pituitary gonadotropin ovarian follicular development, which results in
secretion rises (111) persistentratherthan cyclic estrogensecretion (112)
Rising gonadotropin (FSH, LH) secretion in Exposure to endogenous estrogens occursfora
postmenopausal women is evidence of intact prolonged period oftime creating an environment
hypothalamic function (113). morefavorableformammarytumordevelopment(114)
From JT Stevens (personal communication).
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integration ofnumerous physiological func-
tions, including thirst and water balance,
bodyweight, body temperature, reactions to
stress or emotions, sleep and arousal, and
somatic reactions. Ofcritical interest are the
feedback mechanisms exerted on the hypo-
thalamus and factors released by the hypo-
thalamus in mediating endocrine balance
(Tables 3,4) (103-114).
PRL is capable ofexerting a direct effect
on the growth ofthe mammaryparenchyma
and epithelium (79). Gonadotropins have a
significant influence on ovarian function;
the secretion ofFSH promotes the develop-
ment of the Graafian follicles. LH is also
required to bring the follides to full maturi-
ty and to stimulate estrogen secretion. The
corpus luteum, itself an endocrine gland,
under the influence ofLH secretes estrogen,
progesterone, and inhibin (69). Finally, GH
is also involved in mammary gland develop-
ment and function. Although its exact
mechanism of action is unclear, it directly
stimulates duct growth in hypophysec-
tomized-ovariectomized rats; however, the
presence of estrogen is also necessary to
evoke normal duct development. The pre-
vailing metabolic condition ofan individual
animal or human may significantly influ-
ence mammarygland response to hormones.
It has been demonstrated that estrogen and
progesterone, when given with long-acting
insulin, stimulate considerable mammary
duct growth in hypophysectomized-
gonadectomized rats (72). The growth-sup-
porting effect ofinsulin can be enhanced by
giving thyroxine. A synergistic effect of 11-
desoxycorticosterone and estrogen on mam-
mary duct growth has been observed in the
ovariectomized virgin mouse. The various
endocrine secretions influencing mammary
gland development and function are sum-
marized in Table 3. The maintenance of
regular cycling events is important in
rodents and humans for normal reproduc-
tion (115). There are remarkable differences
in endocrine physiology between estrual and
menstrual animals (Table 4) (103-114).
Spontaneous RodentMammary
Tumors
Spontaneous mammary tumors arefrequent-
ly observed in long term rodent studies
(116). In mice, the development ofsponta-
neous mammary tumors is linked to the
infection of female mice with either an
exogenous MMTV or a less virulent endoge-
nous provirus. A third strain of MMTV
transmitted through the milk and through
the germ line has also been identified in the
European mouse strain GR (9-11). The
exogenous MMTV is an RNAvirus first rec-
ognized to be transmitted through the milk
ofA and C3H strain mothers, the Bittner
factor (117). DBA and RIII are also inbred
strains ofmice that harbor the highly onco-
genic MMTVtransmitted through the milk.
Foster-nursed neonatal mice (i.e., C3Hfor
DBAf) become free ofthe milk-transmitted
MMTV although they retain the genetically
transmitted MMTV, which induces mam-
marytumors latein life (9-11). Inhigh-inci-
dence strains of mice, tumors develop as a
multistep process initiated in preneoplastic
lesions, the hyperplastic alveolar nodules,
which evolve from pregnancy-dependent to
pregnancy-independent adenocarcinomas
(9). Nulliparous mice develop a low inci-
dence ofmammary tumors. Out ofa total of
1361 female B6Cf/CrlBRmice, only 5 ade-
nomas (0.4%), 4 Abroadenomas (0.3%), 10
adenocarcinomas (0.9%), and 7 carcinomas
(0.6%) developed by the end ofa 24-month
follow up (118). Some mammary tumors
that develop in females ofsusceptible strains,
such as C3H, A, DBA, 020, CBA, and cer-
tain sub-strains of Balb/c, are strongly hor-
mone dependent in terms oftheir initiation.
Multiple pregnancies enhance tumor devel-
opment, and final tumorigenic response is
greater in multiparous than in nulliparous
animals. In RIII, BR6, DD, and GR mice,
mammary tumors develop during the first
pregnancy but they regress during lactation.
In some strains ofmice, the growth ofmam-
mary tumors is stimulated by chronic
administration ofestrogens, certain steroidal
contraceptives, progesterone, PRL, and epi-
dermal growth factor (EGF) (9), whereas
hormone deprivation, induced by hypophy-
sectomy, ovariectomy, ovariectomy-adrena-
lectomy, and syalidectomy suppress mam-
marycarcinogenesis (9).
In the rat, the majorityofspontaneously
developed tumors, with the exception of
leukemia, are neoplasms of endocrine
organs or of organs under endocrine con-
trol. Spontaneous mammary tumors devel-
op in females ofvarious strains ofrats such
as August, Albany-Hooded, Copenhagen,
Fisher, Lewis, Osborne-Mendel, Sprague-
Dawley, Wistar, and Wistar/Furth
(9,45,116,119-121). Mammary tumors are
third in incidence among spontaneous
tumors found in the Fisher 344 rat used in
the National Cancer Institute/National
Toxicology Program (NCI/NTP) carcino-
genicity bioassays (116). They are predom-
inantly benign tumors, i.e., fibroadenomas,
fibromas, and more rarely adenomas.
Malignant tumors such as adenocarcinomas
are rare, although they are the most fre-
quent tumors induced by chemical carcino-
gens (24,47). The development ofsponta-
neous tumors varies as a function ofstrain,
age, and endocrine influences. Mammary
gland tumors develop in older females; they
are more frequent in multiparous than in
nulliparus rats. As in mice, hormone with-
drawal inhibits tumor development in rats.
Hormone supplementation, such as chronic
administration of estrogens, increases the
incidence of adenocarcinomas, whereas
chronic administration of prolactin or of
growth hormone stimulates benign tumor
growth (9). The long latency period for
spontaneous tumor development, up to 2
years in susceptible strains to develop a
50-70% tumor incidence, limits the useful-
ness ofthis model forexperimental studies.
Experimental Genotoxic-
induced Rodent Mammary
Tumor Models
Chemicaly InducedMammary
Tumorigenesis
The potential ofchemicals to induce cancer
was recognized almost two centuries ago as
an occupational disease when high inci-
dence ofskin cancer was linked to exposure
to coal tar (2). Although it has not been
proven that human breast cancer is caused
by a given chemical or physical genotoxic
agent, the human population is exposed to
a large number ofenvironmental chemicals
such as polycyclic aromatic hydrocarbons,
nitrosoureas, and aromatic amines, com-
pounds that have been demonstrated to be
carcinogenic in in vivoexperimental animal
models and have been shown to induce
mutagenesis and neoplastic transformation
ofhuman breast epithelial cells in in vitro
models (122). Although a specific etiologic
agent or the conditions that might explain
the initiation and progression ofbreast can-
cer in humans have not been identified,
experimental animal models have proven to
be useful tools for answering specific ques-
tions on the biology of mammary cancer
relative to their validity to the human dis-
ease (60), aswell as for assessing the risk for
breast cancer posed by toxic chemicals
(7,37). In vivoexperimental animal models
provide information not available in human
populations: they are adequate for hazard
identification, dose-response modeling,
exposure assessment, and risk characteriza-
tion, the four required steps for quantifying
the estimated risk of cancer development
associated with toxic chemical exposure
(7). The use of experimental models of
mammary carcinogenesis in risk assessment
requires that the influence ofovarian, pitu-
itary, and placental hormones, among oth-
ers, as well as overall reproductive events,
are taken into consideration because they
are important modifiers ofthesusceptibility
of the organ to neoplastic development
(9,41,44).
Chemically induced mammary tumors
develop by a multistep process. The initial
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step is a biochemical lesion caused by the
interaction of the carcinogen with cellular
DNA. In this interaction the DNA is dam-
aged; ifthe damage is not repaired efficiently,
the result is a mutation, a chromosomal
translocation, an inactivation of regulatory
genes, or more subtle changes not well iden-
tified as yet. Neoplastic development
requires that the lesion becomes fixed, aided
bycell proliferation, and progresses to a third
stage of autonomous growth, which results
in cancer when the lesion acquires the capac-
ity to invade and metastasize (23). Several
carcinogens that induce mammary tumors in
rodents have been identified and extensively
studied for more than 50 years in mice and
for more than 30 years in rats (9). In mice,
mammary carcinomas have been induced
with 3,4-benzopyrene, 3-methylcholan-
threne (MCA), 1,2,5,6-dibenzanthracene,
7,12-dimethylbenz(a)anthracene (DMBA),
and urethane in strains of low spontaneous
mammary cancer incidence. Most of the
mammary tumors induced in mice by chem-
ical carcinogens are adenoacanthomas and
type B adenocarcinomas. They develop after
a relatively long period of time, and their
induction requires multiple applications.
Enhanced tumorigenicity has been obtained
with prolonged hormonal stimulation; how-
ever, the hormone responsiveness of chemi-
cally induced mammary tumors in mice has
not been as thoroughly studied as it has been
in the rat (9,23,60).
In rats, DMBA, MCA, 2-acetylamino-
fluorene, 3,4-benzopyrene, ethylnitrosourea,
butylnitrosourea, and N-methyl-N-
nitrosourea (MNU) have been extensively
used as mammary carcinogens, with DMBA
and MNU used most frequently (9,12-14,
23,41,60). The majority of rat mammary
carcinomas induced by either DMBA or
MNU are hormone dependent. Maximal
tumor incidence is elicited when the car-
cinogens are administered to young virgin
females with an intact endocrine system
(Table 5). These models ofhormone-depen-
dent tumors constitute useful tools for dis-
secting the multistep process ofcarcinogene-
sis and serve as a baseline for testing the car-
cinogenic potential of chemicals in risk
assessment (7).
Radiation-induced Mammary
Tumorigenesis
Ionizing radiation is probably the most
widely acknowledged and studied human
carcinogen (47). Exposure to radiation,
either accidentally or for therapeutic reasons,
has long been associated with a greater inci-
dence ofneoplasms, namely, hematopoietic,
gonadal, and breast (123). The female
breast is one ofthe tissues with the highest
sensitivity to radiation carcinogenesis
(124). Breast cancer developed in irradiated
women shows a strong association with
young age at the time ofexposure, an asso-
ciation not observed in irradiated rodents
(123) but similar to what has been observed
in chemically induced mammary carcino-
genesis in rats (21,38,123). Since contro-
versy exists concerning the shape of the
dose-response curve, the effects offraction-
ated irradiation, and the effect oflow levels
ofradiation (125), animal studies are neces-
sary to address these issues. The rat model
has been widely used in this regard, mainly
since the demonstration in the early 1950s
that a single supralethal dose of X rays to
female Holtzman rats (a Sprague-Dawley
stock) maintained by temporary parabiosis
induced an increased number ofbenign and
malignant mammary tumors within 6
months of exposure (47,126). Sublethal
doses ofdifferent types ofradiation, includ-
ing X rays and neutrons, have been shown
to induce mammary tumor development,
often within a year, with linear dose-effect
relationships for neutrons over the total
dose range and forX rays down to dose lev-
els of0.2 Gy (127-129). Irradiation ofani-
mals with fractionated doses ofy-radiation
has resulted in linear-quadratic dose-
response curves (130). Although most stud-
ies have used whole-body irradiation, local-
ized irradiation also induces mammary
tumors in the ratwithin the irradiated field.
This effect also occurs in women, but
reportedly not in several other animal
species studied, e.g., mice, dogs, and guinea
pigs (127,128,131). In rats, mammary car-
cinomas can be induced by whole-body or
segmental radiation with either X rays, g
rays or neutrons (9,47). Several studies uti-
lizing a variety of fractionated irradiation
protocols, i.e., at 12-hour intervals for 60
days (130), semiweekly for up to 16 weeks
(132), and monthly for up to 10 months
(133), have shown, in general, no increase
in tumor latency, incidence, or total num-
ber of mammary tumors; no sparing or
enhancing effect on mammary tumor devel-
opment have been observed when com-
pared with animals exposed to single doses
of radiation. Some investigators, however,
have reported an increased number of
mammary carcinomas in animals receiving
fractionated doses (132). Sprague-Dawley
and Lewis rats are the most susceptible to
radiation-induced tumorigenesis. AxC,
Fisher, Long-Evans, and Wistar/Furth are
also susceptible, but to a lesser degree. The
mammary tumors developed by irradiated
rats are, in general, hormone-dependent
adenocarcinomas or fibroadenomas. The
hormonal status ofthe female rat is ofpara-
mount importance in determining the out-
come ofirradiation ofthe mammary gland.
Table 5. 7,12-Dimethylbenz(a)anthracene (DMBA) or N-methyl-N-nitrosourea (MNU)-induced mammary
carcinogenesis in female rats of different strains
Mammaryadenocarcinomas
Carcinogen Dose Route Ratstrain Incidence No/rat
DMBA 20mg/animal ig S-D 90 2.7
| - - | |;R j:om.@:F i9'||.|EE 9 3|1wny|~~~~~~~~~~~ ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~--------------
F 1.1
COP 0 O
sBae3ss-le;98lJl IJII Dl IJII1 IcIJb 1°l 6 *1 a 11BIJ 1 _ _|1 110l11 lasm
COP 0 O
1-101~~~~~~~~~~~~~~~~~~~~~~~~~~~~#
44~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~I F
WF 100
ACI 25
5Mg/animal ip NSD 100 1.2
coP 0 0.
ig, intragastric; ip, intraperitoneal; iv, intravenous; sc, subcutaneous; SD, Sprague-Dawley; W-F, Wistar-
Furth; NSD, inbred S0 Lew, Lewis F Fischer 344; AC, A strain x C strain Irish: COP, Copenhagen. NSD
rats received OMBA at a dose of 20 mg divided into four ig doses of 5 mg each and MNU at a dose of 100
mg/kg body weight divided into two iv doses of 50 mg/kg body weight each and at a dose of 150 mg/kg
body weight divided into three iv doses of 50 mg/kg body weight each. Adapted from Russo et al. (23).
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Ovariectomy completely prevents, and
estrogen treatment enhances, radiation-
induced mammary tumor formation
(47,134). The latency period for tumor
development is shortened and tumor inci-
dence is increased considerably in estrogen-
treated rats. The number ofcribriform type
adenocarcinomas (47) and the number of
tumors per tumor-bearing rat (134) are
also increased. Radiation and estrogens,
namely 17p-estradiol (E2) or diethylstilbe-
strol (DES), have been reported to exert
either an additive (135) or synergistic effect
(136,137). The effects ofE2 administration
and irradiation on mammary tumorigenesis
have been reported to be equal for hormone
administration 1 week before or beginning
12 weeks after irradiation, but no additive
effect has been observed when hormone
administration was begun 24 weeks after
irradiation (135). The amplification of
radiation-induced mammary tumorigenesis
by estrogens has been attributed by several
investigators to the effects of this hormone
on the pituitary, an interpretation support-
ed by the observations that DES treatment
of ACI rats and E2 treatment of rats of
three different strains, for example, result in
increased incidence of pituitary tumors
accompanied by marked increases in plasma
PRL levels (137-140). The development of
malignant mammary tumors in these rats
appeared to be associated with the extent of
increase in plasma PRL (141). Mammary
tumor incidence and number or type of
mammary tumors is not modified by irradi-
ation during pregnancy, lactation, or post-
lactational regression in comparison with
irradiation in the virginal state (142), in
contrast to what has been reported in chem-
ically induced mammary carcinogenesis
(21,38). Furthermore, radiation-induced
mammary tumors developed in rats do not
exhibit the age dependency observed in
women (123) or in chemically induced rat
mammary carcinomas (21,38). They do
not exhibit topographic selectivity in their
development because they arise randomly in
thoracic and abdomino-inguinal regions
(9,23). Further studies are needed to clarify
these differences in tumor incidence
between radiation-induced and chemically
induced mammary tumors in rats to vali-
date this model for risk assessment. The
reason for the differences in physiologic
influences on the inductive action ofchemi-
cals and irradiation in rat mammary gland
is not clear. It has been speculated that radi-
ation-induced changes might occur in a
specific stem cell population maintained
throughout the reproductive life, while
chemically induced changes depend upon
the number and rate of turnover of other
types ofmammarygland cells (19).
Modifiers of the Susceptibility Use of Chemicals in Cancer
of the Mammary Gland to Induction
NeoDlasia
Epidemiological Data
Breast cancer in women develops as the
result of a combination of both internal
and external factors. Increased risk is asso-
ciated with nulliparity or late first full-term
pregnancy, early menarche and late
menopause, exposure to ionizing radiations
at a young age, high socioeconomic status,
and family history ofbreast or breast/ovari-
an cancer, including carriers of the newly
identified BRCAI gene (5,123,143).
Among the endogenous factors, early pari-
ty, defined as completion ofa first full term
pregnancy before age 24, has been identi-
fied as a protective factor (5,22,144,145).
Very little is known, however, about the
time of initiation of the carcinogenic
process or what agent(s) cause it. The facts
that early full-term pregnancy is protective
(5), and that a higher incidence of mam-
mary carcinomas has been reported to
develop in women exposed to ionizing
radiations at a young age (123,146) but
not after pregnancy and lactation (22,60)
strongly suggest that, in the human female,
the period between menarche and first full-
term pregnancy might be critical for the
initiation of breast carcinogenesis.
However, the precise time of initiation of
the neoplastic process is not known.
Regarding the site of origin of mammary
neoplasms, there is evidence that tumors
originate in the intralobular terminal ductal
lobular unit (TDLU) or lobule type 1, the
most undifferentiated structure present in
the breast of nulliparous women (23).
Correlative studies have shown an equiva-
lence between the TEB ofthe young virgin
rat mammary gland and the TDLU-lobule
1 of the woman's breast in their carcino-
genic potential (23,147-150). Since
human data are still insufficient for draw-
ing a complete picture of the pathogenesis
ofbreast cancer, adequate experimental sys-
tems mimicking the human disease are
needed for addressing specific questions
whose answer would allow one to elucidate
(1) the influence ofhost factors on the ini-
tiation of the neoplastic process, (2) to
determine whether the susceptibility ofthe
human breast to undergo neoplastic trans-
formation varies with age and reproductive
history, and (3) to determine whether the
susceptibility ofthe breast can be decreased
through modifications of biological and
physiological conditions of the host. We
consider the model of rat mammary gland
carcinogenesis to be the one that more
dosely fulfills the above conditions.
Mammary tumors induced in rodents by
chemical carcinogens have been widely stud-
ied and are useful models ofmammary car-
cinogenesis (16,17,24,26,28,47,52,151-
154). The objective ofthis review is to com-
pare side by side what we know about the
pathology of breast cancer in both humans
and the rat model system to establish a solid
basis for comparison and extrapolation of
knowledge from animal to human. A com-
parative analysis will not only further our
understanding of the biology of the human
disease but will also highlight the gaps in
knowledge that have to be filled in both sys-
tems. The two most widely used experimen-
tal systems of mammary tumorigenesis are
the induction of rat mammary tumors by
administration of either the indirect acting
polycyclic hydrocarbon DMBA, given intra-
gastrically (ig) to Sprague-Dawley rats (28)
and the direct acting carcinogen MNU,
given intravenously (iv) or subcutaneously
(sc) to Sprague-Dawley or Fischer 344 rats,
respectively (155,156). A single ig dose of
DMBA 80-100 mg/kgbodyweight, induces
tumors with latencies that generally range
between 8 and 21 weeks. The final tumor
incidence reaches 100% when the carcino-
gen is administered to intact virgin rats in
their peak of maximal susceptibility, which
in Sprague-Dawley rats occurs between the
ages of40-60 days ofage (38,157). MNU,
given in a single iv dose of25 or 50 mg/kg
body weight, yields tumors with similar
latency and incidence (157). In a compara-
tive studybetween the carcinogenicpotential
of DMBA administered ig at a dose of 20
mg and MNU, given iv at a dose of 50
mg/kg, itwas demonstrated that both induce
approximately equal tumor incidence and
number oftumors per animal with approxi-
matelyequal latency, but a somewhat greater
percentage ofMNU-induced tumors are his-
tologically malignant (32).
For the study of modulating factors,
especially when short-term studies are per-
formed, it has been found that both tumor
latency and tumor histological type are the
most sensitive and reliable end points.
Tumor latency is, in general, inversely relat-
ed to carcinogen dose, whereas the overall
tumor incidence and the number ofmalig-
nant tumors per animal are directly related,
especially when relatively early end points
are used. No such relationship has been
found for benign tumors (32). The number
of tumors per rat or per group and the
number or incidence of malignant tumors
are additional end points useful in analysis
ofdata. Comparison ofdata among labora-
tories requires strict standardization of the
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experimental conditions because consider-
able variations in tumor incidence and
latencies between laboratories and between
experiments in the same laboratory are fre-
quently seen (Table 6) (157-162).
Biological Bases ofthe Susceptibility
ofthe Mammary Gland to
Carcinogenesis
In every tissue, normal or abnormal, cell
composition consists of a balance of three
different cell populations: cycling cells, rest-
ing cells (cells in Go), and dying cells (cell
loss). In the mammary gland, these three cell
populations can be identified through the
study ofthe cell cycle and determination of
the growth fraction and the rate ofcell loss.
The growth fraction refers to the fraction of
cycling cells, while the rate ofcell loss refers
to the fraction ofcells that die or migrate to
other tissues. Both cell cycle time and the
growth fraction determine the number of
cells produced per unit oftime, and the rate
of cell loss determines the number ofcells
lost per unit oftime. The growth ofnormal
cells involves the net increase in cell number
resulting from more cells being born than
are dying. In differentiated tissue or in adult
tissue in which growth has ceased, the num-
ber of cells produced per unit of time is
equal to the number of cells that die. The
higher susceptibility ofthe TEB to neoplas-
tic transformation is attributed to the fact
that the TEB is composed ofan actively pro-
liferating epithelium, as determined by the
mitotic and DNA-labeling indices (Table 7)
(60). These two indices are very high at the
tip of both TEBs and TDs and decrease
toward the ductal or proximal portion ofthe
gland; however, TEBs have higher overall
proliferative activity than TDs. Both mitotic
index and DNA-LI are even lower in ABs
and lobules (17,19). TEBs are also charac-
terized for having the highest growth frac-
tion, which progressively diminishes in the
more differentiated ABs and lobules (19).
By using these cell kinetic parameters, we
have calculated the rate of cell loss in each
one of the compartments of the mammary
tree. Interestingly enough, the TEB is not
only the structure with the highest prolifera-
tive ratio but also with the lowest percentage
of cell loss in comparison with other
parenchymal structures (Table 7). The rate
ofcell loss is very high in the lobular struc-
tures present in the mammary gland of
parous rats. This dearly indicates that the
TEB ofthe young virgin female is the truly
proliferating structure of the gland that
reaches asteadystate onlyafteracquiringfill
differentiation. The differences in prolifera-
tive activity and growth fraction observed
between TEBs and the more differentiated
structures of the mammary gland are also
reflected in variations in the length of the
cell cycle (Tc). Tc in TEBs ofyoung virgin
rats has an average length of 11 hr, increas-
ing to 20.81 and 28.18 hr in TDs and ABs,
respectively. Further mammary gland differ-
entiation, as a consequence of aging and
pregnancy, results in an even longer Tc,
mainly due to a lengthening ofthe G1 phase
ofthe cell cycle (Table 7) (19). The length
ofTc also varies according to the cell type
and to the specific compartment in which
each given cell type is located in. The short-
est Tc is observed in intermediate cells locat-
ed in TEBs, whereas it lengthens when the
same cell type is located in ABs or lobules
(60). These differences in the length ofTc
are mainlydue to differences in the length of
the G1 phase ofthe cell cycle, whereas all the
otherphases remain constant (60).
Mammary epithelial cells metabolize
DMBA to polar metabolites with formation
ofepoxides that cause DNAdamage. When
dissociated mammary epithelial cells of
young virgin and ofparous animals, which
basically represent the cells ofthe TEBs and
of the lobules, respectively, are grown in
vitro, they exhibit different rates of forma-
tion of polar metabolites. TEB cells pro-
duce more polar and less phenolic metabo-
lites than lobular cells; this indicates that
the TEB cells, in addition to their higher
proliferative activity, are also producing
more epoxides, which is manifested by a
higher binding of DMBA to DNA.
Autoradiographic studies performed in vivo
confirm the observation that the greatest
Table 6. Histology of mammary tumors induced by 7,12-dimethylbenz(a)anthracene (DMBA) or N-methyl-
N-nitrosourea (MNU) in female Sprague-Dawley rats
Percent of mammarytumors
Adenocarcinoma
Carcinogen Dose Invasive Noninvasive Fibroadenoma Reference
DMBA 2.5 mg 10 54 30 (157)
13 57 36
3.2 mg 52 48 (158)
75 25
5.0 mg 6 80 14 (157)
4 87 9
5.0 mg 98 2 (159)
8.0 mg 34 66 (160)
16.0 mg 64 26
MNU 35-50 mg/kg 86-94 6-14 (32)
20-30 mg/kg 71-80 20-29
10-15 mg/kg 42-59 41-58
50 mg/kg 94 6 (161)
50 mg/kg x2 93 7 (13)
50 mg/kg x2 97 3 (162)
Adapted from Russo et al. (23).
Table 7. Calculation of cell loss rate and birth rate in rat mammary gland
Growth Cell Labeling S Rate of Terminal [(Ln 2x 10)1 Rate of Cell birth Cell Cell
Rats Structure fracton cycle indices phase(hr) cell birth ducts [TDT] cell loss 0 Actual Theoretic loss loss(%)
Young virgin TEB 0.55 11.65 0.34 7.20 472.00 21.18 327.26 144.73 30.67 472.00 259.67 212.3 44.98
TD 0.39 20.81 0.14 7.47 187.41 53.36 129.90 57.50 30.68 187.41 73.08 114.32 60.99
AB 0.13 28.18 0.04 8.67 46.13 216.75 31.90 14.15 30.67 46.13 5.99 40.14 87.00
Old virgin TD 0.190 18.75 0.077 7.60 101.35 98.70 70.22 31.13 30.71 101.33 19.25 82.07 81.02
TDR 0.054 20.57 0.020 7.60 26.31 380.00 18.24 8.07 30.67 26.31 1.42 24.87 99.70
AB 0.030 30.75 0.008 8.20 9.75 1,025.00 6.25 3.50 35.89 9.75 0.29 9.45 96.99
Parous TD 0.0097 23.92 0.003 7.40 4.05 2,466.66 2.81 1.23 30.37 4.05 0.03 4.01 99.00
AB 0.0049 49.63 0.001 10.13 0.98 10,130.00 0.68 0.29 29.69 0.98 0.0048 0.97 98.90
TEB,terminal end buds;TD,terminal ducts; AB, alveolar buds;TDR,terminal ducts in regression; rate of cell birth = labeling index/S phase length x 104; rate of
cell loss = Ln 2(0.693) x 104;TDT,total doubling time; 0 = rate of cell loss x 100/rate of cell birth; actual cell birth = growth fraction x 104/length of cell cycle;theo-
retic cell birth = growth fraction x 104/total doubling time; cell loss = actual cell birth minustheoretic cell birth; cell loss (%) = cell loss x 100/cell birth rate.
Adapted from Russo and Russo (60).
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uptake of[3H]DMBA occurs in the nucleus
of epithelial cells of TEBs and the lowest
uptake in ABs and lobules, indicating that
the highest DMBA-DNA binding is associ-
ated with the structure of the gland with
the highest replicative properties (Table 8)
(22,163-165). The ability of the cells to
remove DMBA adducts from the DNA is
an indication of their capability to repair
the damage. TEB cells remove formed
adducts less efficiently than lobular cells.
This is attributed to the shorterGI phase of
Tc and not to a lack of reparative enzymes
(Table 8) (22,164).
These studies led us to conclude that
the differentiation of the mammary gland
modifies the following parameters: (1)
gland structure; (2) cell kinetics, decreasing
the growth fraction and lengthening the
cell cycle, mainly the G1 phase; (3) decreas-
ing formation of polar metabolites and
increasing phenolic metabolites; and (4)
decreasing binding of the carcinogen
(Table 8). All the parameters listed above
affect the susceptibility of the mammary
gland to carcinogenesis and should be
taken into account when assessing chemi-
cals for cancer risk.
Factors InfluencingTumorigenic
Response
Influence of Mammary Gland
Differentiation. Mammary cancer in exper-
imental models is the result of the interac-
tion of a carcinogen with the target organ,
the mammary gland. This target, however,
is extremely complex because the mammary
gland does not respond to the carcinogen as
a whole, but only specific structures within
the gland are affected by given genotoxic
agents. The knowledge of the architecture
and cell kinetic characteristics ofthe mam-
mary gland at the time of carcinogen
administration constitutes a necessary initial
step for understanding the pathogenesis of
the disease. It is also required for distin-
guishing those changes induced by the car-
cinogen from changes reflecting normal
gland development, especially when evalu-
ating early tumorigenic response in short
term studies (15-19,22,55,145).
The susceptibility of the mammary
gland to DMBA- or MNU-induced car-
cinogenesis is strongly age dependent; it is
maximal when the carcinogens are adminis-
tered to virgin females between the ages of
40 to 60 days, that is, soon after vaginal
opening and during early sexual maturity
(14,15,162). Active organogenesis and a
high rate of proliferation of the glandular
epithelium are characteristics ofthis period
in which there is also high DMBA activa-
tion (17,20,162). Its significance, however,
is uncertain, because MNU, which is also
most effective at this age, does not require
activation (13,166). The incidence of
DMBA-induced tumors reaches 100%
when the carcinogen is administered to rats
aged 30-55 days, but the highest number of
tumors per animal is observed when the car-
cinogen is given to animals between the ages
of40 and 46 days, coincident with the peri-
od in which the mammary gland exhibits a
high density of highly proliferating TEBs
(18,20,22). This high susceptibility is attrib-
uted to the specific characteristics of the
mammary gland that prevail during that
period of life. Administration of DMBA to
virgin rats induces the largest number of
transformed foci when TEBs are decreasing
in number due to their differentiation into
ABs. These structures, instead ofdifferenti-
ating into ABs, become progressively larger
due to epithelial proliferation, with multi-
layering, secondary lumen formation, and
early papillary projections to the widened
lumen. At this stage, transformed TEBs are
called intraductal proliferations (IDPs) (Fig.
Table8. Mammary gland degree ofsusceptibility
Parameters ofsusceptibility High Intermediate Low
Morphological differentiation TEB>TD>AB>LOB TEB<TD>AB>LOB TD<AB<LOB
Cell kinetics
Ml 7.03 ± 1.00 2.90 ± 2.30 0.09 ± 0.16
DNA-LI 34.40 ± 7.60 14.80 ± 4.70 0.30 ± 0.50
TC 9.93 ± 0.31 18.75 ± 0.99 49.63 ± 6.86
GF 0.55 0.19 0.0097
Lag phase in culture none 24 hr 36 hr
No. ofdoublings in culture 3.04 ± 0.30 3.00 ± 0.14 1.50 ± 0.18
3H-DMBA uptake (grains/nucleus) 6.80 ± 2.60 1.30 ± 0.80 0.70 ± 0.50
DMBA-DNA binding (pmol/DNA-P) 33 25 20
UDS, % of cells 20.0 ± 2.8 37.3 ± 3.06 62.5 ± 3.0
Adduct removal at24 hr 15% 7% 25%
Carcinoma development High Intermediate Lowto none
Benign lesions development Intermediate High Lowto none
TEB, terminal end bud; TD, terminal duct; AB, alveolar bud; LOB, lobules; Ml, mitotic index; DNA-LI, DNA
labeling index; TC, length of the cell cycle (in hours); GF, = growth fraction; UDS, unscheduled DNA
synthesis.
Figure 10. Terminal end buds (TEB;x77) located in Zone C ofthe mammary gland of a 55 day-old virgin rat
become enlarged and darkly stained by 21 days post-DMBA administration; they are called intraductal
proliferations (IDP; x79), which by 35 days post-treatment grow and coalesce to form microtumors that
are not palpable (x129). Whole mount preparations, toluidine blue.
Table 9. Characteristics of the terminal structures of the rat mammary gland: control and experimental
groups
Group no. Structure Size (p) No. cells/section Percentage mitosis
1 TEB 103.0 ± 16.7 61.4± 26.7 7.03± 1.00
2 TD 69.6 ± 9.1 28.6 ± 9.9 2.90 ± 2.30
3 AB 31.9± 4.5 13.9 ± 2.2 0.09± 0.16
4 IDP 226.3 ± 49.0 110.0 ± 21.2 14.90 ±3.30
Size in microns, number of cells/section and percent mitosis represent mean values ± standard deviation.
Student's t-tests were done on all possible comparisons. For structure size, the following comparisons
were significantly different (p<0.001); group 1 vs. 2,3, and 4; group 2 vs. 3 and 4; and group 3 vs. 4. The
percentages of mitoticfiguresfor all groups were similarly significant(p<0.001).
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10, Table 9). Their confluence leads to the
formation of microtumors, which can be
classified histologically as intraductal carci-
nomas. These intraductal carcinomas
progress to invasive carcinomas, developing
various patterns such as cribriform, comedo,
or papillary types (Fig. 10, 11, 12) (15,24).
The histopathological appearance of these
lesions is strikingly similar to the neoplasms
developed in the human breast; a compari-
son between human and rat mammary
tumors is shown in Table 10.
Even though TEB differentiation into
AB is inhibited by carcinogen treatment,
not all the TEBs present in the mammary
gland at the time ofDMBA administration
progress to IDPs. Some TEBs still differen-
tiate into ABs, but their number is always
lower than that in control animals.
Occasional lobular development is
observed, although it is negligible. Some
TEBs become smaller, exhibiting an
atrophic appearance. At this stage, they are
called terminal ducts (TDs). TDs are also
susceptible to neoplastic transformation
and are the main target of carcinogens in
older animals (40). Those TEBs that were
already differentiated into ABs and early
lobular structures before DMBA adminis-
tration do not develop carcinomas. Most of
them either remain unmodified, undergo
dilatation ofthe lumen and give rise to cys-
tic structures, or exhibit epithelial prolifera-
tion and form tubular adenomas (Fig.
12,13). When old virgin females ranging in
age from 180 to 330 days are inoculated
with DMBA, they develop tubular adeno-
mas that exhibit focal areas of malignant
transformation, giving origin to well-differ-
entiated adenocarcinomas with a tubular
pattern. These lesions develop predomi-
nantly in the abdominal glands in which a
higher incidence of tumors is observed in
older animals. The observation that mam-
mary carcinomas arise from undifferentiat-
ed structures of the gland, namely TEBs
and TDs, and benign lesions such as ade-
nomas, cysts, and fibroadenomas arise from
structures that were more differentiated at
the time ofcarcinogen administration indi-
cates that the carcinogen requires an ade-
quate structural target and the type of
lesion induced is dependent upon the area
ofthe mammary gland that the carcinogen
affects. Thus, the more differentiated the
structure at the time ofcarcinogen admin-
istration, the more benign and organized is
the lesion that develops (Fig. 12)
(15,22,24,167). The similarities observed
between benign lesions developed in the
human breast and the rodent mammary
gland (Table 10) are indicative ofa similar-
ity in their pathogenetic pathways as well.
Celloforigin ofrat mammary carcino-
mas. In the rat mammary gland parenchy-
Figure 11. Histological section of an intraductal
proliferation (IDP; x11O), which evolves to in situ
carcinoma, either comedo or cribriform types.
Both subtypes (x150) progress to invasive carci-
noma (x150). H&E.
Figure 12. Pathogenetic pathways of benign and
malignant lesions induced in the virgin rat mam-
mary gland by DMBA. The undifferentiated termi-
nal end buds (TEB) originate adenocarcinomas
progressing from intraductal proliferation (IDP),to
carcinoma (Ca) in situ to develop several sub-
types of in situ and invasive carcinomas. More
differentiated alveolar buds (AB) and lobules
(Lob) originate benign lesions that appear later
than carcinomas (169).
Figure 13. Evolution of benign lesions induced by DMBA in the mammary gland of virgin rats. Alveolar
buds (x70) affected bythe carcinogen develop tubular adenomas and cysts. Whole mounts,toluidine blue
(x98); histological sections stained with H&E (tubular adenoma, x160; cysts,x179).
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ing as early as at 24 hr post-DMBA admin-
istration, but no changes in cell composi-
tion occur in more differentiated structures
such as ABs and lobules. The changes tak-
ing place in TEBs and TDs are limited to
Table 10. Classification of neoplastic and non-neoplastic lesions ofthe rat mammary gland with compari-
son to human lesions
Ratlesion Corresponding human lesion
Adenoma (papillary,tubular, hyperplasia lactating) Intraductal papilloma
Adenoma ofpregnancy
Ductal carcinoma Ductal carcinoma
Cribriform Cribriform
Solid Solid
Invasive Ductal carcinoma invasive
Comedo Comedo
Papillary(NOS) Infiltrating ductal carcinoma (NOS)
Medullary
Others
Lobularcarcinoma insitu
Paget's disease ofthe nipple
Benign Benign
__|P_WAN
Malignant Malignant
Epithelial-stroma neoplasms Epithelial-stroma neoplasms
Fibroadenoma Cystosarcoma phyllodes, benign
Carcinosarcoma Cystosarcoma phyllodes, malignant
Normal lactating gland Normallactating gland
Lobularhyperplasia, notassociatedwith pregnancy
Ductal Cystic dilatation ofducts
Epithelial hyperplasia Epithelial hyperplasia without
Epithelial hyperplasia with
NOS, nototherwise specified. From Russo etal. (23).
Table 11. Cell type distribution in the rat mammary gland
No. of cells Celltype
Structure counted Dark, (%) Intermediate, (%) Myoepithelial, (%)
TEB 2024 76.78 ± 8.6 10.97 ± 7.6 12.23 ± 3.3
TD + ducts 2731 75.64 ± 5.7 12.22 ±4.8 12.12 ±3.6
AB + lobules 2013 62.37 ± 13.3 20.74 ± 12.2 17.26 ± 6.8
Dark and intermediate cell types and myoepithelial cells were counted in terminal end buds (TEB), com-
bined terminal ducts (TD) and ducts, and combined alveolar buds (AB) and lobules in toluidine blue-
stained 1-pm sections of plastic embedded material. Values were expressed as the percentage of the
total ± standard deviation. Student's t-tests were done on all possible comparisons; the differences were
notsignificant.
the dark-cell type, whose proportion
decreases from 76% to 67%, and to the
intermediate cell, whose proportion increas-
es from 11% to 19%. Myoepithelial cells
are unaffected. The trend is a progressive
shift ofcell population distribution, with a
continuous decrease in dark cells and a con-
comitant increase in intermediate cells. By
14 days post-DMBA, intermediate cells
constitute about 40% and 50% ofthe pro-
liferative compartment in TEBs and TDs,
respectively. At this time the morphological
manifestations oftumorigenesis have started
to become apparent. They consist of an
increased number of epithelial cell layers,
greater irregularity of the luminal border,
and progressively larger intercellular spaces,
which in some cases form secondary lumi-
na. These features are indicative ofthe for-
mation of an IDP. The basal lamina
becomes distorted and the surrounding
stroma becomes fibrotic and infiltrated by
inflammatory cells, thus rendering the iden-
tification of myoepithelial cells more diffi-
cult. Between 21 and 40 days post-DMBA
treatment, the descending curve of dark
cells crosses over the progressively ascending
curve ofintermediate cells. By 40 days, the
tumors display a cell distribution of greater
than 65% intermediate cells with less than
35% dark cells. The proportion ofinterme-
diate cells continues to increase with tumor
age, and at 70 days they represent greater
than 75% ofthe total tumoral cell popula-
tion. Dark cells, at this point, have been
reduced to less than 20%, whereas myoep-
ithelial cells remain at approximately 5%.
The 100-day-old tumors are dominated by
intermediate cells, which comprise nearly
90% of the total number of cells (Fig. 14)
(168). The intermediate cells located in
TEBs have a Tc lasting 13 hr. When the
same cell type is located in more differenti-
ated structures, such as ABs, they exhibit a
lengthened Tc lasting 34 hr. These differ-
ences could explain the higher susceptibility
of the intermediate cell of the TEBs to be
affected by the carcinogen, which causes
further expansion of the proliferative com-
partment of the intermediate cells and
Table 12. DNA labeling index in the cell types of
the ratmammary gland
Cell type labeling index
Structure Dark Intermediate Myoepithelial
TEB 14.25± 6.9 39.90± 20.3 16.20± 12.3
TD + Duct 3.95± 3.0 14.46± 11.5 5.16± 9.0
AB + Lob 0.49± 2.2 3.22± 6.9 2.25± 7.9
The DNAlabeling indexwas determined asthe per-
centage of cells incorporating 3H-thymidine in
autoradiographs of mammary gland sections.
Values representthe mean DNA-LI ± standard devi-
ation. TEB, terminal end buds; TD, terminal ducts;
AB + Lob, alveolar buds and lobules combined.
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ma, three types ofepithelial cells have been
described (Fig. 3,5,6; Tables 11,12)
(56,57). The distribution of cell popula-
tions in the mammary gland during car-
cinogenesis varies in TEBs and TDs, start-
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depression in the dark cell population after
initiation ofthe stimulus (60).
Role ofthe stroma in rat mammary car-
cinogenesis. In the preceding sections, we
have shown that mammary carcinogenesis
induced in Sprague-Dawley rats by adminis-
tration ofDMBA is the result ofthe interac-
tion ofthe carcinogen with the TEB. When
damaged by the carcinogen, epithelial cells
ofthe TEB give origin to IDPs; these IDPs
evolve to carcinomas. IDPs are morphologi-
cally distinguishable from TEBs by their
size, which is more than twice that ofTEBs
and by the homogenous cell composition,
which consists preponderandy ofintermedi-
ate cells. The induction ofIDPs is not a rare
event. Within 3 weeks of DMBA adminis-
tration, there are between 10 and 20 IDPs
per mammary gland, and this number
increases with time such that, by 6-10
weeks after treatment, there are approxi-
mately 30 lesions per gland and around 200
per animal. Although IDPs occur in large
numbers following DMBA administration,
the likelihood ofany one IDP progressing to
carcinoma in the intact mammary gland is
lower than that because the maximal
tumorigenic response rarely goes beyond 5
to 6 adenocarcinomas per animal. This phe-
nomenon is attributed to the fact that there
are two different types of IDPs. One type,
initiated IDP (IDP [i]), increases in number
steadily, with a concomitant decrease in the
number ofTEBs, and reaches a plateau by
60 days post-DMBA (Fig. 15). The IDP [i]
is characterized by having a diameter larger
than that of the TEB; it is composed of a
greater number of epithelial cells and does
not elicit a response in the surrounding stro-
ma, remaining unchanged during the whole
post-carcinogen observation period. A sec-
ond type of IDP, initiated and promoted
(IDP [i+p]), appears in the same proportion
and at the same time as IDP [i], by 20-30
days post-DMBA (Fig. 15). They are also
characterized by having a larger diameter
and a greater cell number than TEBs; how-
ever, they elicit a marked stromal reaction,
consisting of collagen deposition and infil-
tration by mast cells and lymphocytes. IDP
[i+p] progresses to carcinoma in situ and to
invasive carcinoma. The fact that not all the
IDPs progress to carcinoma indicates that,
although both IDP [i] and IDP [i+p] are
preneoplastic lesions, there are factors that
regulate the progression of initiated cells,
which affect IDP [i] and IDP [i+p] differ-
ently (169).
The IDP [i+p] is surrounded by a num-
ber of mast cells three times higher than in
both TEBs and IDP [i] (Fig. 16). This
increase in mast cells is accompanied by an
increase in lymphocytes, fibroblasts, collagen
fibers, and proteoglycans. Mast cells are
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Figure 14. Effect of DMBA on mammary epithelial cell population. Dark cells, which predominate in the
normal mammary gland ducts, become progressively replaced by intermediate cells. A slight reduction in
number of myoepithelial cells is observed between 40 and 100 days post-DMBA administration.
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Figure 15. Emergence of microscopic preneoplas-
tic lesions that were intraductal proliferations
(IDP) initiated (i) and initiated and promoted (i+p),
and total number of malignant tumors per animal
(T/an). As the number of terminal end buds (TEB)
decrease with time after DMBA administration,
IDP reach a plateau by 40 days, and IDP (i+p)
reach a peak at 40 days, decreasing in number as
the number oftumor increases (169).
found in different parts ofthe body, and the
mammary gland is not an exception. In the
cytoplasm of mast cells, there are numerous
granules measuring up to 0.8 pm in diame-
ter, which stain metachromaticallywith tolu-
idine blue or alcian blue (170). Mast cells
degranulate, releasinghistamine andheparin,
a heparan sulphate that stimulates cell prolif-
eration (Fig. 17) (171,172). Mast cell lysates
or mast cell-conditioned medium stimulates
locomotion of capillary endothelial cells in
vitro, an effect that is attributed to heparin. It
has been postulated that heparin or frag-
ments ofheparin on the surface ofendothe-
lial cells may selectively bind endothelial cell
mitogens that are also angiogenic (Fig. 17)
(171). An early change observed during the
process oftransformation is the synthesis ofa
large amount ofproteoglycans by IDP [i+p],
which is manifested by the deposition ofan
electron dense material on the cell surface of
the epithelial cells (Fig. 18), and by an
increased reactivity with alcian blue, pH 2.7,
Mastcells
Figure 16. The number of mast cells per square
millimeter is similar in terminal end buds (TEB)
and in intraductal proliferations initiated (IDP [i]).
A threefold increase is observed in IDP initated
and promoted (IDP[i+pl).
Figure 17. The transformed epithelial cells com-
posing the intraductal proliferation (IDP) initiated
and promoted (i+p) interact with stromal ele-
ments, attracting mast cells and stimulating local
regulatory factors that result in increased synthe-
sis of proteoglycans, which in turn affect cell pro-
liferation, desmoplasia, and angiogenesis. GF,
growth factor; TAA, tumor associated antigens.
From Russo and Russo (169).
and periodic acid-Schiff (PAS). The
increased synthetic activity is evidenced by
an increase in uptake of3H-fucose and 3H-
glucosamine (Fig. 19). The number of cells
absorbing these precursors is almost three
times the number found in TEBs and IDP
[i] (Fig. 19); this indicates that the initiated
cells which are progressing to malignancy
secrete heparan-type proteoglycans into the
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Figure 18. Ultrastructure of an intraductal proliferation showing accumulation of electron dense material
(proteoglycans; arrows) on the luminal surface of the transformed epithelial cells and in newly formed
intercellular spaces. Uranyl acetate-lead citrate (x1950).
stroma (Fig. 17) (169). It is not known
whether these proteoglycans are influencing
the response ofthe host by eliciting a higher
mobilization ofmast cells and inhibiting the
cytotoxic effect oflymphocytes or by induc-
ing angiogenesis, desmoplasia, and cell pro-
liferation (Fig. 17). Some ofthese proteogly-
cans, such as heparan sulfate, act as receptors
for growth factors, which in turn initiate an
autocrine response (Fig. 17). Neoplastic
transformation of cells dramatically alters
proteoglycan synthesis in both the tumor
and the surrounding tissues. This process is
thought to stimulate tumorigenic growth by
decreasing the adhesion oftransformed cells
to the extracellular matrix (169). Based on
our own data and those reported in the liter-
ature, it is possible to postulate that the pro-
duction ofproteoglycans allows the IDP to
progress to carcinoma in situ by stimulation
ofcell proliferation and by interference with
an immune reaction against transformed
cells (Fig. 17) (169).
Asynchrony in mammary gland devel-
opment. For the induction of mammary
carcinomas in the rat, the carcinogen is
required to act on a specific compartment
ofthe mammary gland, the TEB. Although
these undifferentiated structures are present
in all the mammary glands, tumor develop-
ment does not occur as a random event in
the six pairs of mammary glands. Tumor
incidence in animals treated with the car-
cinogen between the ages of 20 and 180
days is greater in those glands located in the
thoracic region, whereas glands located in
the abdomino-inguinal area develop a lower
number of tumors. In addition to differ-
ences in tumor incidence as a consequence
of the topographic location of the gland,
there are differences in tumor type that
seem to vary with the age ofthe animal at
the time of carcinogen treatment. Ductal
and papillary adenocarcinomas are more
frequent in both thoracic and abdominal
glands ofyounger animals, whereas adeno-
carcinomas with atubular pattern are found
mostly in abdominal glands and in older
animals (60). The pattern of development
of the rat mammary gland, described as a
branching ofthe parenchyma in ducts end-
ing in TEBs that progressively differentiate
into ABs and lobules, is common to the six
pairs of mammary glands. However, this
process does not occur simultaneously in all
the glands, but differs depending upon the
topographic location of each one of them.
Individual structures, ie., TEBs, ABs, TDs,
and lobules, appear similar in morphology
in all the glands; however, their relative
number and the general architecture ofthe
organ vary notably from one pair ofglands
to another. The most notable ones are the
thoracic mammaryglands; each singlegland
is composed oftwo different layers separat-
ed by connective and muscular tissue. One
ofthe layers is composed ofmore numerous
ABs and small lobules, whereas the adjacent
Fu25 Prngocllslabeled it
TEB IDP {i IDP(i+p)
Figure 19. Percentage of cells labeled with 3H-
fucose and 3H-glucosamine in terminal end buds
(TEB), intraductal proliferation (IDP) initiated (i)
and IDP initiated and promoted (i+p). From Russo
and Russo (169).
one is more extensive and contains thin
long ducts ending in prominent TEBs. The
abdominal glands have a markedly reduced
number ofTEBs, which are located exclu-
sively in the most distal portion ofthe gland
(zone C) (Fig. 2), whereas the middle and
proximal portions A and B show a much
more differentiated appearance. The differ-
ence in number ofTEBs in thoracic versus
abdominal mammary glands is significant.
The number ofTEBs decreases progressive-
lywith aging. The reduction is proportional
in all the glands, and it is mostly due to the
regression ofTEBs to TDs or to their dif-
ferentiation into ABs and lobules. The
higher incidence in ductal carcinomas
observed in thoracic glands is attributed to
the difference in degree of development of
the undifferentiated layer of this gland in
comparison with the glands located in other
topographic areas (40).
Genetic influences. Genetic differences
among individuals may affect their suscepti-
bility to the carcinogenic effect ofchemicals.
Inheritance may also predispose an individ-
ual to develop certain specific types ofcancer
(173). These influences have been carefully
examined in rodent experimental animal
models (174,175). In carefully designed
experiments, it has been demonstrated that
the susceptibility ofrats to the chemical car-
cinogens 2-acetylaminofluorene (AAF),
DMBA, and MNU is genetically determined
(174,175). Isaacs (175) demonstrated that
Buffalo, Lewis, Wistar/Furth, and inbred
Sprague-Dawley rats, all strains of Wistar
genetic background, are highly susceptible to
chemically induced carcinogenesis, whereas
the non-Wistar derived strains (Fischer,
August, ACI, and Copenhagen) are of low
susceptibility. However, there are exceptions
to this rule: the Wistar-derived inbred WN
strain is oflow susceptibility and the non-
Wistar derived Osborne-Mendel is highly
susceptible. Of the commonly used strains,
Sprague-Dawley and Wistar-Furth are the
most susceptible, and Fischer 344 and ACI
rats show intermediate susceptibility.
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Copenhagen rats are essentially completely
resistant, even to the direct application of
DMBAto the gland, although theydo devel-
op fibrosarcomas in response to parenteral
DMBA (174). In extensive analyses compar-
ing DMBA tumorigenesis, mammary gland
growth rate, serum hormone levels, and
DMBA toxicokinetics in female rats ofsever-
al strains and F1 hybrids between the strains
(174,175), no major differences that corre-
lated with susceptibility to tumorigenesis
were found because both susceptible and
resistant strains developed similar percent-
ages ofmalignant changes (60% in resistant,
80% in susceptible). However, macroscopi-
cally detectable tumors developed in 70% of
susceptible glands and 10% of resistant
glands. These findings have been confirmed
by transplantation experiments between
resistant or susceptible strains into Fl
hybrids, between the two strains, and by
direct exposure to DMBA. These observa-
tions indicate that genetic factors govern the
progression from microscopic to macroscop-
ic tumor rather than from normal to histo-
logically malignant epithelium. Furthermore,
these observations demonstrate that resistant
rats possess a dominant suppressor allele for
the gene governing susceptibility. In con-
trast, tumor induction by diethylstilbestrol
(DES) is demonstrable in the ACI strain but
not in Sprague-Dawley rats, although a co-
carcinogenic effect ofDES with DMIBA can
be shown in the Sprague-Dawley strain
(176). Both malignant and benign tumors
are increased by the combined treatment,
but there is a relatively greater increase in
benign tumors. The response to DES oftar-
get organs other than the mammary gland is
also different in these two strains ofrats, but
the mechanisms are not known (177).
Dietary influences. Carcinogenesis can
be modified by nutrients and other dietary
constituents, by other chemicals, and by
endocrine alterations. Excessive fat intake
affects mammary tumorigenesis by reducing
tumor latency, increasing tumor multiplici-
ty, and increasing the fraction ofhistologi-
cally malignant tumors (81,86,158,
178,179). To yield valid results, rats fed
high fat diets must be compared with rats
fed diets that supplysufficient fat for normal
growth and development, at least 4 to 5%
fat by weight, and sufficient essential fatty
acids. The control diet must be equivalent
in all nutrient-to-calorie-ratios to the high
fat diet. The two groups of rats must show
comparable weight gain or controls must be
included to permit evaluation ofcaloric and
specific fat effects on tumorigenesis because
tumor incidence is increased with increased
caloric consumption (180,181). Studies of
the mechanisms by which fat may act have
been reviewed extensively in recent publica-
tions (157,176). No mechanism other than
increased caloric intake has been convinc-
ingly demonstrated to contribute to or be
responsible for the effect of fat because
reduction ofcaloric intake by20, 30 or40%
(180-182), even with a percentage ofcalo-
ries from fat held at a high level, increases
tumor latency and reduces incidence, num-
ber, and size of tumors. However, added
caloric intake and weight gain by rats fed
high fat diets do not account for correlation
ofincreased tumorigenesis with type, as well
as amount, offat (157,166,183-187) or for
results ofpaired-feeding studies (184).
In DMBA-treated rats in which the
energy intake from fat (corn oil) had been
doubled from 25 to 48% of calories (from
10.5 to 24.6% by weight) for the 4 weeks
between weaning and DMBA administra-
tion, mammary tumor incidence increased
significantly; the odds ratio for carcinoma
increased by a factor of 1.6 and for any
tumor by a factor of 5. Body weight and
caloric intake over the 4-week period were
not affected bydietary fat content, provided
that the protein content was adequate for
growth. This result and studies using lard in
the place of corn oil (157,184-186) con-
firmed an effect of fat on the initiation of
tumorigenesis. After DMBA was given, all
rats were fed the same diet with 24% of
calories as fat; a positive effect of caloric
intake on tumor incidence was found to be
independent of dietary fat content. The
high fat diets that enhance tumorigenesis
do not alter significantly: (1) toxicokinetics
of DMBA (188); (2) blood levels of PRL,
17P-estradiol, progesterone, or LH or the
patterns of hormone secretion through the
estrous cycle (185,186,189); or (3)
[3H]thymidine labeling ofmammary gland
epithelial DNA before or after carcinogen
exposure (190). Although induction of
both hormone-dependent and hormone-
independent tumors responds to dietary fat
content (185,186), high fat diets do not
increase the growth rate of tumors as mea-
sured bypalpation (157,178).
The influence ofcaloric use byvoluntary
orinvoluntaryexercise is underinvestigation.
Unfortunately, results are variable and show
both increased and decreased tumorigenesis
in exercised rats (190). Standardization of
methods with measurement ofenergy intake
and expenditure and of body composition
are needed to permit comparison and inter-
pretation ofresults. There is renewed interest
in the effect of omega-3 fatty acids on
growth and metastasis of transplanted, as
well as induced, mammary tumors in rats.
However, the results are not entirely consis-
tent within or among laboratories, probably
in part because acceptance ofthedietsbyrats
varies (191).
The influence ofcaffeine on the mam-
mary gland is of interest because of the
postulated relationships between coffee
consumption and fibrocystic disease or
breast cancer, although significant relation-
ships have not been demonstrated in epi-
demiologic studies. Highly variable
responses to coffee and caffeine have been
shown in rats and mice (159,192,193). In
DMBA-treated Sprague-Dawley rats given
coffee or caffeine in drinking water before
and during DMBA initiation ofmammary
tumorigenesis, tumor multiplicity, but not
tumor incidence or tumor latency, was
reduced in comparison with rats given
DMBA alone. When coffee or caffeine
were given after DMBA administration,
there was no consistent effect on tumorige-
nesis (192). Results were the same when
rats were fed a purified diet that contained
5 or 20% fat (by weight) (193). In mice
given similar amounts ofcoffee or caffeine,
DMBA-induced or murine mammary
tumor virus-induced tumor multiplicity
was increased but other parameters of
tumorigenesis were not affected. Caffeine
increased mammary gland development in
mice, apparently by increasing the response
to trophic hormones (159).
Epidemiologic studies strongly indicate
that alcohol intake is a risk factor for breast
cancer (194,195). The increased risk is 1.5-
to 3-fold, depending upon the population
studied and the amount of alcohol con-
sumed. In experimental animals, alcohol
may have an inhibitory effect on the liver
metabolism of certain compounds such as
nitrosamines that are carcinogenic in a vari-
etyofsites. In rats treatedwith MNU, which
does not require metabolic activation, daily
doses ofethanol (5 mg/kgbodyweight) were
associated with increased numbers ofmalig-
nant tumors but not significant alteration of
tumorlatencyorincidence (195).
Impact of Hormones and
Growth Factors in Mammary
Carcinogenesis
The role ofhormones on the development
ofthe mammary gland has been the subject
of numerous studies which over the years
have generated a bibliography too volumi-
nous to be comprehensively cited here
(66,101,196). Despite of the amount of
knowledge available, the subject is continu-
ously under scrutiny and revision as new
growth factors are discovered or character-
ized and hormone receptors are reassessed in
their locations and functions. Nevertheless,
dassic knowledge has established that mam-
mary gland development occurs only in the
presence ofa functional ovary. The pubertal
development ofthefemale rat, therefore, has
been divided, based on ovarian morphology
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and serum gonadotropin levels, into the fol-
lowing phases: 1) neonatal period, from
birth to day 7; 2) infantile period, from day
8 to day 21; 3) juvenile period, between 22
and 32 days; and 4) peripubertal period,
encompassing the next 3 days of life (68).
The ovary, in turn, depends on pituitary
gonadotropins for its development and
function; receptors for LH and FSH actively
bind these hormones as early as the infantile
period, although the stimulated secretion
consists ofandrogens rather than estrogens.
Pituitary FSH interacts with GH and PRL
in modulating ovarian steroidogenesis, a
function that is also influenced by epineph-
rine, which is secreted by the adrenal medul-
la (68). The ovary also secretes inhibin and
activin, non-steroidal glycoprotein hor-
mones that feed back to the pituitary, specif-
ically in an FSH-release suppression func-
tion (70). The response of the mammary
gland to these complex hormonal interac-
tions results in developmental changes that
permanently modify the architecture and
the biologic characteristics ofthe gland. The
mammary gland, in turn, responds selective-
ly to given hormonal stimuli depending
upon specific topographic differences in
gland development, which modulate the
expression ofeither cell proliferation or dif-
ferentiation, as described above.
Ovarian Steroid Hormones and
Growth Factors
The ovary secretes three main classes of
steroid hormones (estrogens, androgens,
and progestins). Their relative and absolute
amounts change periodically during the
phases of the menstrual cycle in humans
and the estrous cycle in rodents. The three
main natural estrogenic hormones synthe-
sized by ovarian follicles are estradiol,
estrone, and estriol. Estrogens are critically
involved in mammary gland development
and are also essential for eliciting a tumori-
genic response with chemical or physical
carcinogens (47,197). Estrogens act on
mammary epithelial cells through three dif-
ferent mechanisms: a direct receptor-medi-
ated effect, a mammary stroma-mediated
effect, and an in vivo stimulation of pitu-
itary PRL levels, which in turn, stimulates
lobuloalveolar development in the mamma-
ry gland (67,76). Estradiol is the most
potent and abundant estrogenic hormone
and is responsible for the beginning of
estrus. It is oxidized in the liver to estrone,
which in turn can be hydroxylated to estri-
ol. Estriol decreases the effects ofestradiol,
thus acting as a partial antagonist.
Continuous administration ofsupraphysio-
logical doses ofestrogens, either by implan-
tation of pellets or subcutaneous injection,
induces a high percentage of rat mammary
tumors, which are predominantly adenocar-
cinomas (154), whereas low doses given
over long periods induce fibroadenomas
(198). The tumorigenic effects ofestrogens
are dependent on a functional pituitary
gland because they are ineffective in
hypophysectomized rats (101, 199).
Secondary changes in the pituitary gland
have been found in rats after prolonged
administration of estrogen. Treatment of
female F344 rats with DES causes a 10 to
16-fold enlargement ofpituitary glands, an
increase in number of hyperplastic PRL-
secreting cells that exhibit hyperplasia ofthe
rough endoplasmic reticulum, and
decreased secretory granules. Estrogens
stimulate the growth ofDMBA- and MCA-
induced mammary tumors when adminis-
tered at low doses; however, the develop-
ment and growth ofthese adenocarcinomas
are inhibited byhigh doses of17,-estradiol,
estriol, estrone, and DES. This biphasic
effect might be explained bythe stimulation
ofPRL secretion by low levels ofestrogens,
and the inhibition of PRL by large doses
(197). Ovariectomy either prior to or very
soon after MCA or DMBA administration
suppresses rat mammary carcinoma devel-
opment; it also inhibits tumor growth or
causes tumor regression in rats already bear-
ing tumors. Reactivation of tumor growth
in ovariectomized rats can be accomplished
by administering moderate levels of 17p-
estradiol or DES (101). The combination
ofestrogen and PRL is essential for the neo-
plastic transformation of the mammary
epithelium, because no tumors are induced
by administration of estrogens following
hypophysectomy. Hypophysectomy alone,
on the other hand, does cause tumor regres-
sion (197).
Progesterone, one of the main hor-
mones produced by the corpus luteum
(200), when implanted in female rats
increases the frequency ofboth MCA- and
DMBA-induced mammary tumors in
either intact or ovariectomized rats but
does not do so in ovariectomized-adrena-
lectomized rats (25,27,64,65,201-205).
Chronic administration of progesterone to
neonatally androgenized rats at varying
times after DMBA treatment causes a
marked increase in development and
growth of mammary carcinomas (101);
however, moderate to high doses of this
hormone, in combination with high doses
ofestrogen, inhibit the growth of DMBA-
induced rat carcinoma (28). The latter
treatment causes intense hyperplasia in the
normal rat mammae and also causes ovari-
an atrophy. It is curious that a moderate
dose level ofprogesterone, by itselfa mam-
mary tumorigen, coupled with estrogen at
high dose levels, provides a therapeutic
hormonal milieu considerably more effec-
tive than treatment with estrogen alone at
high doses (12,28,101). It is important
that moderate doses of progesterone or
estrogen (natural or synthetic) can enhance
the growth of polycyclic aromatic hydro-
carbon-induced rat mammary carcinomas.
Inhibins are heterodimeric growth fac-
tors, members of the transforming growth
factor c (TGF-,) superfamily. These glyco-
protein hormones are produced in the
gonads; their known function is a feedback
mechanism to the pituitary for inhibiting
the production and release of FSH
(69,70,85). The granulosa cells of the
ovary in most species and human luteal
cells have been identified as the sites of
inhibin synthesis in the female. Inhibin
mRNA has been detected in extragonadal
tissues; recently its synthesis by the rat
mammary epithelium in response to
human chorionic gonadotropin (hCG)
treatment and during pregnancy has been
reported (69). These findings and the
observation that inhibin-deficient trans-
genic mice develop gonadal tumors (206)
indicate that this peptide has a tumor sup-
pressor activity, in addition to autocrine or
paracrine growth and differentiation mod-
ulator functions.
Pituitary Hormones
Two endocrine bodies, the hypothalamus
and the pituitary gland, have a role in the
control ofprolactin secretion. The anterior
pituitary is able to synthesize and release
large quantities of prolactin upon the
destruction of hypothalamic connections.
The hypothalamus inhibits prolactin secre-
tion via production of prolactin-inhibiting
factor (PIF), which is in turn controlled by
the amount ofcatecholamines released from
nerve endings in the hypothalamus. Rising
catecholamine concentrations result in
release of PIF and reduced release of pro-
lactin by the pituitary. A decrease in cate-
cholamine release produces the opposite
effect. Estrogen acts on the pituitarygland to
increase prolactin release and on the hypo-
thalamus to decrease PIF, thus increasing
prolactin secretion by dual mechanisms. In
addition, the thyroid hormones, acting
directly on the pituitary, also increase pro-
lactin secretion (199). The influence ofpro-
lactin on the induction and growth ofspon-
taneous or oncogene-induced mammary
neoplasia in rats and mice is well established
(207-211). Grafting of multiple pituitary
isographs to mice significantly increases the
incidence of mammary tumors. This same
procedure used on nulliparous and multi-
parous rats greatly increases this tumor inci-
dence over that of the nongrafted controls,
regardless of parity status (212). In the rat,
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production of median-eminence hypothala-
mic lesions in females results in a significant
increase in spontaneous mammary neoplasia.
Such lesions in the rat increase prolactin
secretion and decrease or prevent secretion of
other anterior pituitary hormones. All of
these effects indicate that prolactin is the
major pituitary hormone in spontaneous
mammary oncogenesis and that an
endocrine imbalance can be tumorigenic in
the rat and the mouse. There is a direct cor-
relation between prolactin levels in serum
and the genetically influenced susceptibility
of several rat strains to induced mammary
tumorigenesis (213). The following treat-
ments and physiological states cause hyper-
prolactinemia in female rats bearing DMBA-
or MCA-induced mammary tumors and sig-
nificantly increase growth of these neo-
plasms: adrenalectomy; pregnancy; pseudo-
pregnancy; pituitary homografts; pituitary
tumors; hypothalamic lesions; hypothalamic
implants ofsteroids; certain neuroendocrine-
influencing drugs such as reserpine, per-
phenazine, and haloperidol; and high dietary
fat. Hypoprolactinemia induced by a num-
ber ofchemicals (e.g., ergot alkaloids, cydic
imide derivatives, lysergic acid, ergoline
derivatives, L-dopa, pargyline, antirat pro-
lactin serum) causes significant decreases in
growth ofinduced tumors (101). The reduc-
tion in serum prolactin levels, which is gen-
erally dose related, is associated with an
increase in hypothalamic catecholamines and
PIF (214,215). An excess of prolactin is
often mitogenic in normal rodent mammary
tissue and appears to be a critical regulatory
hormone for controlling mitotic activity of
mammary epithelium (i.e., deficiency causes
hypoplastic epithelium and excess results in
mammary hyperplasia). Prolactin-induced
changes in mammary mitotic activity might
influence the susceptibility ofthe epithelium
to chemical, physical, and viral oncogenic
agents. Clearly, fluctuations in levels ofpro-
lactin influence the growth of mammary
tumors in the rat; however, there does not
appear to be a correlation between normal
range levels of serum prolactin and either
fast- or slow-growing mammary tumors
(213). It is possible that variations in onco-
gene-induced growth might be the result of
the sensitivity of mammary tumor cells to
prolactin; thus, small changes in prolactin
secretion, not detected by serum analysis,
could markedly influence tumorcell prolifer-
ation. That prolactin is also the keyhormone
in mouse mammary neoplasia is supported
by the observation that treatment with ovine
prolactin or reserpine or the induction of
hypothalamic lesions greatly increases the
incidence ofsuch tumors in this species. In
many strains ofmice, prolonged above-nor-
mal prolactin secretion invariably accompa-
nies an increase in mammary tumors.
Treatment of nulliparous C3H/HeJ mice
with either 2-bromo-a-ergocryptine or 6-
methyl-8-,-ergoline-acetonitrile, both pro-
lactin-suppressing drugs, virtuallyprevents or
sharply reduces mammary tumorigenesis. It
appears that prolactin is not only an impor-
tant hormonal stimulant of mammary
tumorigenesis but is essential in the neoplas-
tic transformation of the mouse mammary
gland (101,213). Prolactin is the principal
pituitary hormone in the development,
maintenance, and transformation ofhyper-
plastic alveolar nodules (HAN). Prolactin
secretion-suppressing substances reduce the
number ofHANs, as well as the number of
mammary tumors. Although prolactin by
itself plays an important role in induction
and growth ofmammary tumors in rodents,
it may also act synergistically with other hor-
mones (e.g., estrogens) or by possibly react-
ing with other host factors. The simultane-
ous development of mammary tumors and
neoplasia ofthe pituitary has been observed.
Pituitary tumors have been known to devel-
op directly as effects ofestrogen on pituitary
luteotrophs (216) and indirectlybyinjuryof
dopaminergic tuberoinfundibular neurons in
the basal hypothalamus, which secrete pro-
lactin-inhibiting factor (217). The uninhib-
ited activity of these neurons with further
stimulation by estrogen is the basis of the
pituitary tumor development. The high
spontaneous pituitary neoplasia invarious rat
strains is considered to be, at least in part,
due to hyperestrogenism in aging females
(218). The estrogen-induced and sponta-
neous pituitary tumors have been demon-
strated to be primarily prolactin secreting.
Data seem to substantiate that estrogens are
mammary carcinogens in rodents because of
their stimulatory effects on prolactin secre-
tion. However, the role ofprolactin in the
development of breast cancer in women is
uncertain (219).
Placental Hormones and Growth
Factors
The reproductive process, since its initiation,
is deeply dependent ofhormonal and neural
factors. The maternal corpus luteum, which
is instrumental in the preparation of the
endometrium forimplantation, is in turn res-
cued by the luteotropic hormone chorionic
gonadotropin secreted by the primitive tro-
phoblast of the blastocyst within hours of
implantation. Inwomen, hCG stimulates the
corpus luteum tosynthesize progesterone, 17-
hydroxyprogesterone, estradiol, inhibin, and
relaxin (98). hCG also stimulates the synthe-
sis ofinhibin in the rat corpus luteum (69).
Relaxin plays amajorrole in the maintenance
ofearly pregnacy because it causes the relax-
ation of the myometrium and, in conjunc-
tion with progesterone, reduces spontaneous
uterine activity (220). The corpus luteum
constitutes the major source ofprogestational
steroids until the ninth week of gestation
when the placenta becomes the sole source of
these hormones, as demonstrated by the lack
ofeffect ofovariectomy after the ninth week
on the progression ofpregnancy. The placen-
ta has evolved in mammals as an efficient
mechanism for transporting nutrients to the
fetus, excreting waste products into the
maternal blood stream, and influencing
maternal physiology through the newly
secreted placental and fetal hormones. In
humans, the placenta becomes fully devel-
oped bythe end ofthe first trimester ofpreg-
nancy. The functional unit is the chorionic
villus, which is composed ofan outer layer of
trophoblast, the syncytiotrophoblast, and an
inner layer, the cytotrophoblast, both
arranged around a core ofloose connnective
tissue traversed by numerous fetal capillaries.
The syncytiotrophoblast synthesizes proges-
terone through hydroxylation and side-chain
cleavage of cholesterol. The syncytiotro-
phoblast also produces and secretes hCG and
human placental lactogen (hPL). The
cytotrophoblast is the source ofseveral neu-
ropeptides first discovered in the brain, such
as gonadotropin releasing hormone (GnRH),
thyrotropin releasing hormone (TRH),
somatostatin, corticotropin releasing factor
(CRF), and propiomelanocortin. It also syn-
thesizes the gonadal peptide inhibin (220).
Chorionic gonadotropin (CG) is a polypep-
tidehormone composedofaand , subunits.
The a subunit is identical to that ofpituitary
gonadotropins, whereas the [B subunit differs
in amino acid sequence (221). The most
widely known action of CG is the mainte-
nance ofthe corpus luteus during pregnancy.
The action ofCG is identical to that of the
pituitary gonadotropin LH, with a small
degree of FSH activity (69,222). CG pro-
ducedbytheplacentaofrats, mice, and ham-
sters is structurally similar to human CG
(223-226).
Insulin
Insulin is a hormone synthesized by the 5
cells of the islets of Langerhans, the
endocrine portion ofthe pancreas (98). It is
produced in the form ofa biosynthetic pre-
cursor of higher molecular weight, proin-
sulin. The structure ofinsulin has been rela-
tively stable throughout evolution, and most
mammalian insulins have similar biological
potencies in all species (98). Glucose is the
major stimulus for both the synthesis and
secretion of insulin. Insulin, in turn, regu-
lates glucose entry in most tissues (227). It
exerts an acute metabolic effect, i.e., glucose
tolerance; it also elicits growth responses and
evokes late or long-term biological effects
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(228). The development, function, and
even tumorigenesis of the mammary gland
depend on insulin for expression. The mam-
mary gland primordium of the 17-day rat
embryo grows and penetrates the mes-
enchyme in response to insulin (44). Insulin
plays an essential role in the expression of
terminal differentiation of the mammary
epithelium. Physiological levels ofinsulin, in
the presence of cortisol and prolactin,
induce the synthesis of casein by mouse
mammary explants in vitro and promote the
induction of ca-lactalbumin in cultured rat
mammary tissue, even in the absence ofglu-
cose in the medium (228). Insulin or a glu-
cose solution administered to rats bearing
DMBA-induced mammary carcinomas sig-
nificantly increases tumor growth; when
these two substances are administered in
combination, the treatment produces a
much larger tumor growth response
(229,230). Alloxan diabetes in tumor-bear-
ing rats induces a significant regression of
mammary tumors, quantitatively resembling
the regression observed with ovariectomy or
hypophysectomy. Administration of insulin
activates mammary carcinoma growth in
intact rats and reactivates growth in regress-
ing tumors in hypophysectomized rats
(231,232). Studies have shown that insulin
plays an important role in regulating tumor
estrogen receptors (233). Insulin has a direct
growth-promoting effect on rat mammary
carcinoma cells in vitro (232).
Androgenic Steroids
Androgenic steroids can be classified in two
categories: adrenal androgens (androstene-
dione, 11 -hydroxyandrostenedione, dehy-
droepiandrosterone, and dehydroepiandros-
terone sulfate), and testicular androgens
(testosterone) (234). Testosterone, which is
synthesized by the Leydig cells of the testis
in most mammalian species, is themajor cir-
culating androgen in the male (235).
Endogenous androgen is responsible for the
development ofsexual dimorphism in mam-
mary development in rodents (44). During
embryonal life, the target tissue for andro-
gen is the mammary mesenchyme, which
undergoes condensation under the influence
of androgen secreted by the animal's own
testes (44). Before the advent of antiestro-
gens, androgens were used for the treatment
of advanced breast cancer. Androgens dis-
play both an estrogenic and an antiestro-
genic effect, depending upon the nature of
the receptor they activate (236). There is
evidence that androgens behave as full estro-
gens when they bind to the estrogen recep-
tor. At high concentrations, dehydrotestos-
terone induces estrogen-specific responses
and stimulates the growth of DMBA-
induced rat mammary tumors. Other
androgens, like the 5-androstene-3, 17,B-
diol metabolite of the adrenal DHEA and
5a androstane-3P,17p-diol, which have a
high affinity for the estrogen receptor, are
estrogenic at near physiological concentra-
tions and, through this mechanism, might
stimulate the growth ofhormone-dependent
mammary cells (236). Androgens exert an
antiestrogenic effect through the inhibition
of the estrogen-induced increase in proges-
terone receptor (236). These various effects
could explain the contradictory observations
on the effect of androgens on mammary
tumorigenesis reported in the literature.
DMBA-induced rat mammary tumors,
which regress after hypophysectomy and
ovariectomy, also regress after treatment
with the androgenic steroids testosterone,
dihydrotestosterone, 2-methyldihydrotestos-
terone propionate, various enol derivatives
of dihydrotestosterone, dromostanolone
propionate, and 2-methyl-17p-hydroxy-5a-
androstan-3-one (25,27,237-241). When
moderate to high doses of androgenic
steroids are given to rats with DMBA-
induced tumors, an occasional mammary
neoplasm is often enhanced, perhaps owing
to partial conversion of the androgenic
steroids to estrogenic agonists (101,240).
Androgen inhibition of DMBA-induced
carcinoma growth in rat mammae can be
reversed by high doses of prolactin (241).
Addition of testosterone to cell cultures of
DMBA-induced mammary carcinomas
inhibits DNA synthesis (242). Studies on
the interactions of androgens with different
receptors in estrogen target tissues have pro-
vided some information on the mechanisms
of action of androgens in hormone-depen-
dent tumors. The mechanism of the estro-
genic activity of the androgens seems to be
fairly well understood. It is known that
androgens such as testosterone can be arom-
atized into estrogen, for example, in the
hypothalamus. Androgens might also dis-
place free active estrogens from their plasma
binding protein, and they might act as full
estrogens through their efficient interaction
with the estrogen receptor. In contrast, the
mechanism by which androgens are able to
act as antiestrogens is not yet fully under-
stood (236).
Thyroid Hormones
Thyroid hormones are synthesized by the
thyroid gland under the regulation of the
anterior pituitary hormone thyroid stimu-
lating hormone (TSH). Thyroid hormones
have major actions in almost all tissues;
they control essential functions such as the
regulation of energy metabolism and pro-
tein synthesis (243). Alterations in thyroid
function, namely hypothyroidism, have
been associated with a greater incidence of
breast cancer (244-247). A statistically sig-
nificant linear trend in the odds ratio for
breast cancer has been found in women
with subnormal levels of circulating free
thyroxine (T4) with long duration ofovula-
tory activity (248) and in women receiving
thyroid medication for fertility problems
(249); an excess in numbers ofdeaths from
breast cancer has been reported in women
with nontoxic nodular goiter (250).
However, the number ofstudies is insuffi-
cient for drawing definitive conclusions on
this relationship, and not all the studies
support these conclusions (246,247).
In rodent models it has been found that
thyroid hormones have a direct effect on
growth and differentiation ofthe mammary
gland (243-247). This effect is attributed
in part to the induction ofan increased sen-
sitivity of the tissues to estradiol and pro-
lactin through modulation of the number
and the affinity characteristics of their
respective receptors (247). Hypothyroidism
in mice is associated with delayed lobu-
loalveolar development and a greater degree
ofpostlactational involution ofthe mamma-
ry gland. Hyperthyroidism leads to
increased development ofthe mammary tis-
sue; however, it does not affect thepostlacta-
tional phase of mammary gland regression
(244-247). The fact that thyroid function
also affects pituitary and ovarian function
makes it difficult to determine the specific
effects ofthyroid hormone excess or insuffi-
ciency on mammarygland development and
carcinogenesis. Studies performed in primi-
parous mice, made mildly hypothyroid by
ingestion of thiouracil or mildly hyperthy-
roid by administration of thyroxine have
revealed that the estrous cycles remain nor-
mal, and the levels ofprolactin and the mor-
phology and degree of mammary gland
development in both groups of animals are
similar to those of euthyroid animals.
However, the incidence of spontaneous
tumors is significantly lower in the hypothy-
roid animals at 1 year after removal of the
pups (246,247). It is not clear whether thy-
roid hormones have a positive or a negative
influence on mammary gland development
and on carcinogen-induced mammary carci-
nomas in the rat (247). Conflicting results
include the improved mammary gland
development in castrated or estrogen-treated
castrated rats after thyroidectomy. These
effects were counteracted by T4 administra-
tion. These observations suggest that the
hypothyroid condition increases the sensitiv-
ity of the mammary glands to estrogens
(247). With respect to mammary tumorige-
nesis, various studies have shown enhance-
ment, inhibition, or no effect in rats made
hyperthyroid by administration of thyroid
hormones or hypothyroid by administration
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of goitrogens. Despite the large number of
studies (101), the direct or indirect influ-
ence ofthyroid hormones on the develop-
ment, growth, and progression of induced
rat mammary carcinomas is still unresolved .
Current Knowledge in Human
Breast Carcinogenesis
Human Breast Development
Two important concepts in breast develop-
ment are that this organ is one offew that is
not completely developed at birth and that
it reaches its full differentiation only
through the hormonal stimuli induced by
pregnancy and lactation (147). The study
ofbreast development reveals that the breast
ofpostpubertal nulliparous women is com-
posed oflobular structures reflecting differ-
ent stages of development. Lobules type 1,
also called terminal ductal lobular unit
(TDLU), are the most undifferentiated
ones; they are composed ofclusters of6-11
ductules per lobule. Lobules type 2 evolve
from the previous ones and have a more
complex morphology, being composed ofa
higher number of ductular structures per
lobule. During pregnancy, lobules type 1
and type 2 progress to lobules type 3, which
are characterized byhaving an average of80
ductules or alveoli per lobule (Fig. 20).
Lobules type 4, which are present only dur-
ing the lactational period of the mammary
gland, regress to type 3 afterweaning (147).
The structure most frequently found in the
breast ofnulliparous women ofall ages is the
lobule type 1, which comprises 50-60% of
the total lobular component, followed in
frequency by the lobules type 2 (30-35%);
lobules type 3 are the least frequent
(5-10%). In the breast of premenopausal
parous women, on the other hand, lobules
type 3 predominate, comprising 80-100%
of the total lobular component (149,150,
251). These data are relevant to the fact that
women with a history of early pregnancy
have a 0.5 relative risk (RR) of developing
breast cancer in comparison with nulli-
parous women (RR = 1.0). This effect is
attributed to a greater degree ofglandular
differentiation induced by the reproductive
process (41,226,252,253). We have shown
that there are significant differences in the
content and relative percentage of lobular
structures present in the breast according to
the parity status ofa woman. In nulliparous
women, lobules type 1 and type 2 are almost
constantly present throughout their lifespan;
the lobules type 2 decrease in number after
menopause. In the parous woman's breast,
the lobules type 3 are the most frequent
structures present. Only after the fourth
decade of life is there an increase in the
number oflobules type 1 due to the regres-
Figure 20. Whole mount preparations of sexually mature female breasts showing the three main lobular
structures: the least differentiated lobules type 1 (LOB 1; x99), which progress to lobules type 2 (LOB 2;
xl18), and these progressto lobulestype 3 (LOB 3; xl21). Toluidine blue.
Figure 21. Lobules type 1, present in the breast of nulliparous women [whole mount (x105) and histologi-
cal section (xl18), upper panels], give origin to ductal carcinoma in situ[whole mount(x94) and histologi-
cal section (x135), lower panels]. Whole mountstoluidine blue; histological sections H&E.
sion ofthe more differentiated lobules type
3. At the end ofthe fifth decade oflife, the
breast of both nulliparous and parous
women contains predominantly lobules type
1 (251). The undifferentiated structures,
namely lobules type 1 and 2, which pre-
dominate in the breast of nulliparous
women, also exhibit a high rate ofcell pro-
liferation, whereas the more differentiated
lobules type 3 present in the breast ofparous
women exhibit a lower proliferative index
(147).
Pathogenesis ofHuman Breast
Cancer
An important concept that emerged from
our study of breast develoment is that the
lobules type 1, or TDLU, have been identi-
fied as the site of origin of ductal carcino-
ma in situ (Fig. 21) (23,254). Supporting
evidence to this observation is based on a
comparative study of autopsies performed
in women with and without breast cancer
(23) in which we found that, in cancer-
associated breasts, the number of hyper-
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Figure 22. Lobules type 2 [whole mount (xlO5) and histological section (x105), upper panels] give origin to
lobular carcinoma (Ca) in situ [whole mount (x135) and histological section (x94), lower panels]. Whole
mounts, toluidine blue; histological sections, H&E.
plastic terminal ducts, atypical lobules type
1, and ductal carcinoma in situ originated
in lobules type 1 were significantly higher
than in autopsies of women free of breast
cancer (Fig. 21). An additional finding of
these studies was that lobules type 2 give
rise to the lobular carcinoma in situ (Fig.
22), whereas lobules type 3 and 4 originate
more benign breast lesions (Fig. 23)
(23,149,150). We concluded from these
observations that each specific compart-
ment ofthe breast gives origin to a specific
lesion.
Transformation ofHuman Breast
Epithelial Cells
The time of initiation of the carcinogenic
process in women is not known. The
observation that early full-term pregnancy
is protective and that a higher incidence of
mammary carcinomas occurred in women
exposed to ionizing radiation at ages
younger than 19 (146), but not after preg-
nancy and lactation (22,60) strongly sug-
gests that, in the human female, the period
between menarche and first full-term preg-
nancy might be critical for the initiation of
breast carcinogenesis. Evidence document-
ed in the previous section indicates that
tumors originate in the terminal ductal
structures most distal from the nipple
(22,60,254). However, for answering the
critical question of whether the lobules
type 1 and type 2 are more susceptible than
lobules type 3 to carcinogenesis, we have
developed an in vitrosystem for manipulat-
ing the conditions ofthe breast epithelium
that mimic the in vivo situation. For this
purpose we have used mammoplasty speci-
mens obtained from women that under-
went voluntary surgery for breast reduction
(122,148). Fresh tissues were digested with
collagenase and hyaluronidase and the
epithelial components of the gland were
isolated as organoids. These structures were
separated by micromanipulation and lob-
ules type 1, 2, or 3 were identified, depend-
ing on the branching pattern or number of
ductules per lobular unit, and placed in
culture. The behavior in vitro varied
depending upon the lobule type plated.
Lobules type 1 and 2 attached to the dishes
promptly and started growing in a logarith-
mic fashion, whereas the lobules type 3 had
a long lag phase before they attached and
started growing. The proliferative activity
of these lobular structures, measured by
uptake of3H-thymidine and expressed as
DNA-labeling index, was higher in both
lobules type 1 and 2 than in lobules type 3.
In in vitro conditions, the number ofdou-
blings per unit of time was higher in lob-
ules type 1 and 2 versus lobules type 3
(255,256). Primary cultures derived from
organoids representing the lobules type 1,
2, and 3 were treated while in the log phase
of growth with the chemical carcinogens
MNU, DMBA, methyl-nitro-N-nitroso-
guanidine (MNNG), or benzo(a)pyrene
(BP) for 24 hrs. The cells were followed for
several passages until the first evidence of
transformation such as changes in cell mor-
Figure 23. Pathogenetic pathway of human breast
cancer. The terminal end bud (TEB) described in
the virgin rat mammary gland is considered to be
equivalent to the lobule type 1 (LOB 1) or terminal
ductal lobular unit (TDLU) of the woman's breast.
TD, terminal ducts; LOB 2, lobule type 2; LOB 3,
lobule type 3; LOB 4, lobule type 4; DCIS, ductal
carcinoma insitu, IDC, invasive ductal carcinoma;
LCIS, lobular carcinoma in situ, LIC, lobular inva-
sive carcinoma; Hyperp LOB, hyperplastic lobule;
Fib aden, fibroadenoma; Sci aden, sclerosing
adenosis; Apoc cysts, apocrine cysts. From Russo
et al. (23).
phology, loss of contact inhibition, and
anchorage independent growth became evi-
dent. The carcinogens induced changes in
cell shape by increasing the number ofsur-
face microvilli and by decreasing the
cell-cell interaction. The typical domes
that are characteristic of normal breast
epithelial cells were lost when the cells were
treated with the carcinogens, an effect
attributed to the induction ofalterations in
contact inhibition and pattern of growth.
When these cells were plated in agar
methocel, they formed colonies (Fig. 24)
(148). Of 52 human breast samples stud-
ied, the most important features found
were the increased ability of the breast
epithelial cells to survive in and form
colonies in agar methocel and the expres-
sion of multinucleation. However, the
response was only observed in epithelial
cells derived from breast tissues containing
lobules type 1 and 2. These phenomena
were not observed in breast cells derived
from lobules type 3 (148,255).
We concluded from these studies that
primary cultures ofhuman breast epithelial
cells are affected by chemical carcinogenes,
which induce transformation phenotypes
whose expression depends upon the degree
ofgland development and in vivo cell pro-
liferation of the donor's breast (148,255).
The finding that lobules type 1 and 2 are
more susceptible to express phenotypical
changes oftransformation in vitro supports
our previous observations that lobules type
1 and type 2 are the site oforigin ofcarci-
nomas, whereas lobules type 3, which are
not associated with the development of
malignant lesions, are not affected by car-
cinogens in vitro; this further emphasizes
the concept that gland differentiation has a
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Figure 24. Primary cultures of human breast
epithelial cells obtained from lobules type 1 form Figure 25. Terminal end buds (TEB), underthe regular hormonal stimuli ofthe menstrual cycle, differenti-
colonies in agar methocel after in vitro treatment ate into alveolar buds(AB) in the nulliparous female. Pregnancy and lactation furtherthe differentiation of
with DMBA. Control cells treated with dimethyl AB to lobules. Arrows indicate unidirectional differentiation of TEB into AB and lobules. Postlactational
sulfoxide (DMSO) do not form colonies. Colonies involution does not restore the undifferentiated conditions ofAB and TEB. From Russo and Russo (41).
are stained with neutral red.
protective effect in vivo and that this effect
is also manifested in cells in vitro, render-
ing them resistant to carcinogen-induced
neoplastic transformation.
Unified Concept of Mammary
Carcinogenesis
Comparative studies ofhumans and rodents
have allowed us to determine that mammary
cancer originates in undifferentitated termi-
nal structures of the mammary gland. The
terminal ducts of the lobules type 1 of the
human female breast, the site of origin of
ductal carcinomas, have many points in
common with the terminal end buds ofthe
rat and mouse mammary gland, the site of
origin ofrodent mammary carcinomas. Cell
replication in the lobules type 1 of the
human breast has its highest peak during
early adulthood at a time during which the
breast is more susceptible to carcinogenesis.
TEBs of the rat mammary gland also have
theirhighestproliferative activity, bindingof
carcinogen to the DNA, and low repair
capabilities when the animals are young and
more susceptible to chemical carcinogens.
Both in humans and in rodents, the mam-
mary gland proliferative activity and suscep-
tibility to carcinogenesis decrease with age.
We have been able to demonstrate that the
carcinogen acts on the TEB and that this
structure is the one that evolves to intraduc-
tal proliferation, carcinoma in situ, and inva-
sive carcinoma (Fig. 12). The undifferentiat-
ed lobule type 1 of the human breast has
also the highest proliferative activity and in
vitro binding ofthe carcinogen to the DNA
and, more importantly, it expresses pheno-
types of cell transformation after this treat-
ment. These data indicate that in both
rodents and humans the compartment in
which the target or stem cell is found is the
determinant factor in the initiation event.
Several factors regulate the susceptibility of
the stem cells to neoplastic transformation,
namely, the topographic location of the
mammary gland, age, and reproductive his-
tory of the host. Epidemiologic findings
support this concept, because a higher inci-
dence ofbreast carcinoma has been reported
in nulliparous women and in women having
an earlymenarche, factors that are indicative
of a higher susceptibility to breast cancer,
which is also coincident with the higher sus-
ceptibility to carcinogens observed in young
virgin rats due to the presence ofundifferen-
tiated structures in the mammary tissue such
as TEBs (Fig. 25). Thus, the protection
afforded by early pregnancy and late menar-
che in humans or bypregnancy or treatment
with pregnancy-related hormones such as
hCG in rodents drives the mammary gland
irreversibly towards the differentiation path-
way (Fig. 25) instead ofthe neoplastic trans-
formation pathway (Fig. 26). The relevance
of our work lies in the validation of the
rodent model system for understanding
human breast cancer and the demonstration
that both differentiation and cell prolifera-
tion, which are important in the initiation
ofcarcinogenesis, are parameters that can be
modulated for developing strategies for
breast cancerprevention.
Experimental Rodent
Mammary Tumor Models
in Risk Assessment
Humans and all living species are exposed
either acutely or chronically to numerous
physical and chemical agents that can cause
health hazards. The effects of those expo-
sures can be manifested immediately, as
acute toxic reactions, or can take years. In
this latter case, the association of disease
development to genotoxic agent exposure
might become blurred, first, because oflack
of awareness on the part of the patient or
the treating physician that the exposure
occurred, second, that the course ofthe dis-
ease might have been modified by endoge-
nous and exogenous factors which might
have acted synergystically or might have
inhibited certain aspects ofthe process, and
third, that even though exposure to a given
agent might be recollected and acknowl-
edged by both patient and physician, that
agent might not have been recognized to be
causative of disease or a genotoxic agent.
The identification of specific physical and
chemical agents as causative of human dis-
ease, namely cancer, and the demonstration
in experimental systems that those agents
can be mutagenic and/or carcinogenic have
led to the development ofmethods for mon-
itoring human exposure to given mutagens
and carcinogens, and several biomarkers
have been developed for this purpose
(257,258). Epidemiologic studies have
proven to be invaluable tools for identifying
agents responsible of the causation of
human disease, such as benzene in acute
myelogenous leukemia (AML) (259,260),
thus allowing their classification as known
human carcinogens (EPA Class A, IARC
Class I). The knowledge ofthe health effects
ofthese known carcinogens has led the U.S.
Occupational Safety and Health
Administration (OSHA) to adopt specific
requirements for risk assessment, biomoni-
toring and adoption ofsafety levels ofexpo-
sure (259). However, epidemiological stud-
ies are limited because observations on the
end effects of given physical or chemical
agents may be performed several years after
exposure and only relatively high risks will
be detected. One additional problem is that
epidemiologic data reveal historical expo-
sures but do not provide information on the
potential riskofnew or untested chemicals.
The need to evaluate health risks associ-
ated with toxic chemical exposure has led to
the development of risk assessment as an
organized approach for 1) hazard identifica-
tion for toxic chemicals and potential health
effects that might occur in exposed popula-
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Figure 26. Terminal end buds (TEB) evolve to alveolar buds (AB) or lobules if pregnancy or human chori-
onic gonadotropin (hCG) stimulate them towards the differentiation pathway. If a carcinogen reaches the
target(TEB) during the susceptibility period, itdiverts this evolution tothe neoplastic transformation path-
way, developing instead into intraductal proliferation (IDP), intraductal carcinoma (IDCa), and invasive
adenocarcinoma (AdCa). From Russo and Russo (41).
tions; 2) dose-response modeling; 3) expo-
sure assessment; and 4) risk characteriza-
tion. In 1976, the U.S. Environmental
Protection Agency (EPA) adopted risk
assessment and risk management as a two-
step process for evaluating risk and policy
development for reduction of exposure,
respectively (7). The use of rodent animal
models for hazard identification has proven
to be useful for carcinogenicity testing.
Rodent models are advantageous because
they are informative in the absence of
human data, they allow the assessment of
risk, testing ofdose effects, and the charac-
terization of risk; however, the extrapola-
tion of carcinogenic data obtained in
rodents to human risk requires us to address
basic concerns when evaluating unknown
chemicals. First, it needs to be determined
whether a tumorigenic response elicited in a
rodent model by a specific treatment is a
credible indicator for potential human risk.
Proper statistical evaluation and mathemati-
cal analysis are required for determining the
predictive value of a treatment-induced
tumorigenic response (261). The assess-
ment of the carcinogenic potential of an
unknown agent requires the use ofa model
in which the multifactorial conditions that
affect a human being during interaction
with a given chemical are reproduced. This
requirement should be better fuffilled by in
vivo than by in vitro models. The ideal con-
dition would be a model in which an ani-
mal is subjected to the same conditions as
the human, for example, household pets.
Cats that develop spontaneous mammary
carcinomas which metastasize, like in
humans (50), and dogs that develop mam-
mary cancer in response to progestogens
(49) have been proposed as adequate mod-
els. Monkeys, which are more similar to
humans than any other species in menstrual
cyclicity and endocrinologic conditions
(51), should represent the optimal model;
however, time, space, and economical
restraints have hindered the wider use of
these models in favor ofthe more economi-
cal rodent models. Rodent models ofchem-
ically induced mammary carcinogenesis
have provided valuable information on the
optimal host conditions, as well as on dose
and route of administration to be utilized
for eliciting maximal tumorigenic response
(12-20,25-29). Knowledge gained through
the study of these models has allowed
researchers to determine that tumor inci-
dence, number of tumors per animal,
tumor type, andlatencyperiod ofchemical-
ly induced mammary neoplasms are dose
dependent, as well as dependent upon the
age and reproductive history of the animal
at the time of carcinogen exposure
(12-20,25-29,52). Because known geno-
toxic agents are highly tumorigenic when
given to young animals and the induced
mammary neoplasms have a short latency
period, the background induced incidence
of spontaneous mammary tumors in
rodents, which, although variable, develops
late in life, becomes less relevant. These
models have allowed researchers to test the
influence of dose in the tumorigenic
response. Carcinogen dose has been found
to inversely affect tumor latency and direct-
ly affect the overall tumor incidence and
number of tumors per animal; this effect
has been observed exclusively for malignant
but not for benign tumors (32). Thus, it
can be concluded that treatment-related
increases in the incidence and number of
mammary carcinomas per animal are dose
dependent, rather than a reflection of the
maximum tolerated dose (MTD) used for
routinetoxicitytesting.
Studies of normal mammary gland
development and chemically induced
rodent mammary carcinogenesis have pro-
vided useful information for clarifying how
the interplay ofovarian, pituitary, and pla-
cental hormones, while influencing the
development and physiology of the mam-
mary gland, modulate its response to given
chemical carcinogens (12-22,25-29,
38-42,64-66). Rodent experimental mod-
els have beenuseful for testing the hormone
dependence ofmammary tumors. Although
the role played by the most important
endogenous hormones in the development,
progression, and regression ofrodent mam-
mary neoplasia has been fairly well charac-
terized (43,101,244-247), the fact that
they are essential elements in normal body
functions implies a no-adverse effect level
threshold for the normal effects and the
interplay of feedback mechanisms (262).
Hormones may not be carcinogenic in
themselves, but they may allow the neoplas-
tic transformants initiated by proximal car-
cinogens to establish and grow by modify-
ing the host or target tissue (115) or
through a variety of mechanisms, such as
the activation ofviruses, induction ofrecep-
tors for carcinogens, or the initiation of
DNA synthesis following carcinogenic
insult. A point ofconcern in evaluating the
cancer risk posed by any given substance is
the role played by the route of exposure.
The literature available on the carcinogenic
potential of direct- and indirect-acting
genotoxic agents indicates that route of
exposure is fairlyspecific foreach given type
of agent. Indirect-acting liposoluble poly-
cyclichydrocarbons aretraditionally admin-
istered intragastrically (27,18-22), whereas
the direct-acting MNU has to be rapidly
injected intravenously (12-14,101). The
fact that topical applications of DMBA in
the mammary gland and intraperitoneal
injections of MNU elicit a tumorigenic
response indicates that alternative routes
may also be indicative of the carcinogenic
potential of a given substance. However,
the large variability in tumorigenic response
reported by different laboratories using
identical carcinogens, doses, and routes and
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even intralaboratory variations makes it dif-
ficult to generalize on the appropriateness
of route selection for carcinogenic testing
and risk assessment. Despite these concerns,
careful comparisons ofthe pathogenesis and
histopathology of mammary cancer in
humans and rodents have provided a reli-
able basis for extrapolating carcinogenic
data from experimental models to the
human condition (23,24).
Conclusions and Future
Directions
This work describes and compares experi-
mental in vivo models presently used for
assessing the mammary carcinogenic poten-
tial of given chemical and physical agents
and addresses the need for identifying those
models that provide information on the
mechanisms involved in cancer initiation
and progression in the human population.
The main problems identified in this study
are the complexity and multistep nature of
the carcinogenic process, the lack ofunder-
standing of the mechanism(s) involved in
the initiation and progression ofthe disease,
and the lack of identification of a specific
etiologic agent or agents of human breast
cancer. Long-term studies in rodent models
have been traditionally used, mainly due to
the susceptibility of the rodent mammary
gland to develop both spontaneous and
chemically induced neoplasms. The useful-
ness of chemically induced mammary
tumors lies in their hormone dependence;
the high frequency ofadenocarcinomas his-
tologically similar to human breast cancers;
the possibility they offer for analyzing the
initiation, promotion, and progression steps
ofcarcinogenesis; and the baseline informa-
tion they provide in risk assessment.
Classical studies of these models have
allowed researchers to identify the optimal
host conditions, as well as the dose and
route ofadministration to be used for elicit-
ing maximal tumorigenic response.
Chemically induced mammary tumors
develop by a multistep process, which
begins as a biochemical lesion caused by the
interaction of the carcinogen with cellular
DNA. In this interaction, the DNA is dam-
aged and, ifthe damage is not repaired effi-
ciently, the result is a mutation, chromoso-
mal translocation, inactivation ofregulatory
genes, or more subtle changes that are not
yet well identified. Neoplastic development
requires that the lesion becomes fixed, aided
by cell proliferation, and progresses to a
third stage of autonomous growth, which
results in cancer when the lesion acquires
the capacity to invade and metastasize.
Several carcinogens such as MCA, DMBA,
and MNU have been extensively studied in
mice and rats. DMBA and MNU have been
the most frequently used; the majority of
the mammary tumors induced in rats by
either one of these agents are hormone-
dependent adenocarcinomas. The observa-
tion that maximal tumor incidence is elicit-
ed when the carcinogens are administered
to young virgin female rats has led to
important discoveries on the role of mam-
mary gland development and differentia-
tion in cancer initiation. Hormonally
induced differentiation and the interplay of
ovarian, pituitary, and placental hormones
have been identified as powerful modula-
tors ofthe tumorigenic response elicited by
genotoxic chemicals.
Humans and all living species are
exposed either acutely or chronically to
numerous physical and chemical agents that
can cause health hazards. The human popu-
lation is exposed to a large number ofenvi-
ronmental chemicals such as polycyclic aro-
matic hydrocarbons, nitrosoureas, and aro-
matic amines that are known to be carcino-
genic in in vivoexperimental animal models
and are known to induce mutagenesis and
neoplastic transformation ofmammary cells
in in vitro models. The potential ofchemi-
cals to induce cancer in humans has been
recognized for over two centuries. The
identification ofspecific physical and chem-
ical agents such as radiation, coal tar, and
benzene as causes of human cancers and
leukemias has led to the classification of
some agents as known human carcinogens
(EPA Class A, IARC Class I). The demon-
stration that these agents can be mutagenic
or carcinogenic in experimental systems has
constituted the basis for developing bio-
markers for monitoring human exposure.
The knowledge ofthe health effects ofthese
known carcinogens has led OSHA to adopt
specific requirements for risk assessment,
biomonitoring, and adoption ofsafetylevels
of exposure (7). Confirmation of these
effects through epidemiological studies,
however, is limited because observations on
the end effects ofgiven physical or chemical
agents might be performed several years
after exposure and only relatively high risks
will be detected. Because epidemiological
data reveal historical exposures but do not
provide information on the potential risk of
new or untested chemicals, experimental
animal models should provide the necessary
information for accurately predicting the
human carcinogenic potential of a given
substance. The utilization ofrodent animal
models for hazard identification has proven
to be useful for carcinogenicity testing.
Rodent models are advantageous because
they are informative in the absence of
human data, they allow the assessment of
risk, the testing ofdose effects and the char-
acterization ofrisk. However, the extrapola-
tion of carcinogenic data obtained in
rodents to human risk requires basic con-
cerns be addressed when evaluating
unknown chemicals. First, it should be
determined whether a tumorigenic response
elicited in a rodent model by a specific
treatment is a credible indicator for poten-
tial human risk. Proper statistical evaluation
and mathematical analysis are required for
determining the predictive value ofa treat-
ment-induced tumorigenic response. The
assessment of the carcinogenic potential of
an unknown agent requires the use of a
model in which the multifactorial condi-
tions that affect a human being during
interaction with a given chemical are occur-
ring. The relevance ofexperimental animal
models should be validated by careful com-
parisons with the human condition. The
greater the similarities between the two sys-
tems, the greater the predictive value and
the validity of extrapolations from rodents
to humans (263-266).
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